1
|
Hilton JF, Ott PA, Hansen AR, Li Z, Mathew M, Messina CH, Dave V, Ji X, Karpinich NO, Hirschfeld S, Ballas M, Zandberg DP. INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunol Immunother 2024; 73:44. [PMID: 38349570 PMCID: PMC10864474 DOI: 10.1007/s00262-023-03623-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Accepted: 12/25/2023] [Indexed: 02/15/2024]
Abstract
Combining immunotherapies with distinct mechanisms of action has the potential to overcome treatment resistance and improve outcomes. The inducible T-cell co-stimulator (ICOS) agonist feladilimab is directed at enhancing T-cell activation and function, thereby promoting an antitumor response. INDUCE-2 (NCT03693612) was a Phase I/II, open-label, two-part study evaluating the anti-ICOS agonist feladilimab in combination with the anti-CTLA-4 antibody tremelimumab in patients with select advanced solid tumors. Objectives of Part 1 were to determine the safety, tolerability, and recommended phase 2 dose (RP2D) of feladilimab in combination with tremelimumab. In Part 2, the antitumor activity of the combination (administered at the RP2D determined in Part 1) was to be assessed in patients with relapsed/refractory head and neck squamous cell carcinoma. Primary endpoints included the rates of dose-limiting toxicities (DLTs), adverse events (AEs), AEs of special interest, and serious AEs. Secondary endpoints included overall response rate, while biomarker assessment was exploratory. A total of 26 patients were enrolled, 18 (69%) of whom had completed the study at end date. One patient, in the highest dose group (24/225 mg feladilimab/tremelimumab), experienced a DLT 18 days after the first dose of study treatment. All patients experienced at least one AE; AEs led to treatment discontinuation in four (15%) patients. Partial response was observed in one patient. Feladilimab in combination with tremelimumab was well-tolerated but showed limited efficacy. Based on the totality of data from Part 1, it was decided not to continue with Part 2.
Collapse
Affiliation(s)
- John F Hilton
- The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
| | | | | | - Zujun Li
- New York University, New York, NY, USA
| | - Matthen Mathew
- Columbia University Irving Medical Center, New York, NY, USA
| | | | | | | | | | | | | | - Dan P Zandberg
- UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, 15232, USA.
| |
Collapse
|
2
|
Jerzak KJ, Bouganim N, Brezden-Masley C, Edwards S, Gelmon K, Henning JW, Hilton JF, Sehdev S. HR+/HER2- Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review. Curr Oncol 2023; 30:5425-5447. [PMID: 37366894 DOI: 10.3390/curroncol30060411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 05/26/2023] [Accepted: 05/31/2023] [Indexed: 06/28/2023] Open
Abstract
The approval of CDK4/6 inhibitors has dramatically improved care for the treatment of HR+/HER2- advanced breast cancer, but navigating the rapidly-expanding treatment evidence base is challenging. In this narrative review, we provide best-practice recommendations for the first-line treatment of HR+/HER2- advanced breast cancer in Canada based on relevant literature, clinical guidelines, and our own clinical experience. Due to statistically significant improvements in overall survival and progression-free survival, ribociclib + aromatase inhibitor is our preferred first-line treatment for de novo advanced disease or relapse ≥12 months after completion of adjuvant endocrine therapy and ribociclib or abemaciclib + fulvestrant is our preferred first-line treatment for patients experiencing early relapse. Abemaciclib or palbociclib may be used when alternatives to ribociclib are needed, and endocrine therapy can be used alone in the case of contraindication to CDK4/6 inhibitors or limited life expectancy. Considerations for special populations-including frail and fit elderly patients, as well as those with visceral disease, brain metastases, and oligometastatic disease-are also explored. For monitoring, we recommend an approach across CDK4/6 inhibitors. For mutational testing, we recommend routinely performing ER/PR/HER2 testing to confirm the subtype of advanced disease at the time of progression and to consider ESR1 and PIK3CA testing for select patients. Where possible, engage a multidisciplinary care team to apply evidence in a patient-centric manner.
Collapse
Affiliation(s)
- Katarzyna J Jerzak
- Odette Cancer Centre, Sunnybrook Health Sciences, Toronto, ON M4N 3M5, Canada
| | - Nathaniel Bouganim
- Cedars Cancer Centre, McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| | | | - Scott Edwards
- Dr. H. Bliss Murphy Cancer Center, St. John's, NL A1B 3V6, Canada
| | - Karen Gelmon
- Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada
| | | | - John F Hilton
- The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada
| | - Sandeep Sehdev
- The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada
| |
Collapse
|
3
|
Ng TL, Taljaard M, Savard MF, Stober C, Nicholls S, Vandermeer L, Thavorn K, Hampel C, Shamess J, Mills N, Hilton JF, Clemons M. Abstract OT2-21-01: A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adjuvant chemotherapy (REaCT-5G). Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-ot2-21-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Current guidelines recommend the use of granulocyte colony-stimulating factors (G-CSF) as primary prophylaxis to prevent febrile neutropenia (FN) associated with commonly used breast cancer chemotherapy regimens. Filgrastim (FIL) is a short-acting G-CSF injection that requires daily subcutaneous injection starting 24-72 hours after chemotherapy for 5 to 10 days. Pegfilgrastim (PEG) is a long-acting, pegylated formulation that requires a single injection 24-72 hours after chemotherapy. G-CSF causes bone pain in approximately 70% of patients, which can be severe in over 25% of cases. While registration trials for PEG showed bone pain from PEG was comparable to FIL when given for a median duration of 11 days, many oncologists are now only prescribing FIL for 5 days based on a multicenter RCT showing that 5 days of FIL is non-inferior to 7 or 10 days of FIL in terms of FN and treatment-related hospitalizations. Furthermore, the cost of 5 days of FIL ($CA 721.55 for 300 mcg dose) is half of the price of a single dose of PEG ($CA 1424.63). Therefore, if 5 days of FIL leads to significantly less bone pain, this may improve health-related quality of life (HR-QoL) for patients, improve adherence to G-CSF, and improve cost-effectiveness. Methods: Patients receiving neo-/adjuvant chemotherapy for early stage breast cancer requiring primary FN prophylaxis with G-CSF will be approached for this pragmatic, multicenter, open-label superiority RCT. Using the Rethinking Clinical Trials (REaCT) methodology that incorporates an integrated oral consent model, eligible and consented patients will be randomized to either 5 days of FIL or one day of PEG with each cycle of chemotherapy. The primary endpoint is bone pain during the first 5 days after G-CSF injection using area under the curve (AUC) of the daily pain score from days 1-5 (AUC score 0 to 40) of the Bone Pain Diary. Secondary endpoints include incidence of FN and treatment-related hospitalizations, incidence of chemotherapy delay, dose-reduction, or discontinuation, incidence of chemotherapy-related mortality, rate of G-CSF compliance, healthcare resource utilization, HR-QoL, and cost-effectiveness. Participants will also complete a Treatment Preference Questionnaire (TPQ) exploring the relative importance of different factors in deciding between PEG vs. 5 days of FIL both before randomization and at the end of the study. To achieve 80% power in an ANCOVA analysis and assuming 5% are loss to follow-up, the planned sample size is 232 patients (116 per arm). The randomization (1:1 ratio) will be stratified by treatment center (4 centers) and chemotherapy regimen (taxane-based vs. anthracycline-based in the first 4 cycles). Results: The study opened for enrollment on June 9, 2021. As of July 6, 2021, the study has opened at one site, and 13 patients have been randomized.Conclusion: This will be the first RCT using a patient-reported Bone Pain Diary that was co-developed by patient partners to measure bone pain between 5 days of FIL vs. PEG. In collaboration with patient partners, the study incorporates a tool (TPQ) that explores factors that may be important in deciding between PEG and FIL, with the aim of translating the findings of this study into real world clinical practice.
Citation Format: Terry L. Ng, Monica Taljaard, Marie-France Savard, Carol Stober, Stuart Nicholls, Lisa Vandermeer, Kednapa Thavorn, Claudia Hampel, Jennifer Shamess, Natalie Mills, John F. Hilton, Mark Clemons. A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adjuvant chemotherapy (REaCT-5G) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr OT2-21-01.
Collapse
Affiliation(s)
| | | | | | - Carol Stober
- Ottawa Hospital Research Institute, Ottawa, ON, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Dent S, Fergusson D, Aseyev O, Stober C, Pond G, Awan AA, McGee SF, Ng TL, Simos D, Vandermeer L, Saunders D, Hilton JF, Hutton B, Clemons M. A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. Curr Oncol 2021; 28:5073-5083. [PMID: 34940066 PMCID: PMC8700071 DOI: 10.3390/curroncol28060427] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 11/23/2021] [Accepted: 11/28/2021] [Indexed: 12/30/2022] Open
Abstract
PURPOSE The optimal frequency for cardiac monitoring of left ventricular ejection fraction (LVEF) in patients receiving trastuzumab-based therapy for early breast cancer (EBC) is unknown. We conducted a randomized controlled trial comparing 3- versus 4-monthly cardiac monitoring. PATIENTS AND METHOD Patients scheduled to receive trastuzumab-containing cancer therapy for EBC with normal (>53%) baseline LVEF were randomized to undergo LVEF assessments every 3 or 4 months. The primary outcome was the change in LVEF from baseline. Secondary outcomes included the rate of cardiac dysfunction (defined as a decrease in the LVEF of ≥10 percentage points, to a value <53%), delays in or discontinuation of trastuzumab therapy, and cardiology referral. RESULTS Of the 200 eligible and enrolled patients, 100 (50%) were randomized to 3-monthly and 100 (50%) to 4-monthly cardiac monitoring. Of these patients, 98 and 97 respectively underwent at least one cardiac scan. The estimated mean difference in LVEF from baseline was -0.94% (one-sided 95% lower bound: -2.14), which exceeded the pre-defined non-inferiority margin of -4%. There were also no significant differences between the two study arms for any of the secondary endpoints. The rate of detection of cardiac dysfunction was 16.3% (16/98) and 12.4% (12/97) in the 3- and 4-monthly arms, respectively (95% CI: 4.0 [-5.9, 13.8]). CONCLUSIONS Cardiac monitoring every 4 months was deemed non-inferior to that every 3 months in patients with HER2-positive EBC being treated with trastuzumab-based therapy. Given its costs and inconvenience, cardiac monitoring every 4 months should be considered standard practice. Registration: NCT02696707, 18 February 2016.
Collapse
Affiliation(s)
- Susan Dent
- Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, ON K1H 8L6, Canada; (S.D.); (A.A.A.); (S.F.M.); (T.L.N.); (J.F.H.)
- Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (C.S.); (L.V.); (D.S.)
| | - Dean Fergusson
- Clinical Epidemiology Program, The Ottawa Hospital Research Institute, The University of Ottawa, Ottawa, ON K1H 8L6, Canada; (D.F.); (B.H.)
| | - Olexiy Aseyev
- Thunder Bay Regional Cancer Care Northwest, Thunder Bay Regional Health Sciences Centre, Thunder Bay, ON P7B 6V4, Canada;
| | - Carol Stober
- Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (C.S.); (L.V.); (D.S.)
| | - Gregory Pond
- Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada;
| | - Arif A. Awan
- Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, ON K1H 8L6, Canada; (S.D.); (A.A.A.); (S.F.M.); (T.L.N.); (J.F.H.)
| | - Sharon F. McGee
- Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, ON K1H 8L6, Canada; (S.D.); (A.A.A.); (S.F.M.); (T.L.N.); (J.F.H.)
| | - Terry L. Ng
- Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, ON K1H 8L6, Canada; (S.D.); (A.A.A.); (S.F.M.); (T.L.N.); (J.F.H.)
| | - Demetrios Simos
- Stronach Regional Cancer Center, Southlake Regional Health Care Centre, Newmarket, ON L3Y 2P9, Canada;
| | - Lisa Vandermeer
- Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (C.S.); (L.V.); (D.S.)
| | - Deanna Saunders
- Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (C.S.); (L.V.); (D.S.)
| | - John F. Hilton
- Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, ON K1H 8L6, Canada; (S.D.); (A.A.A.); (S.F.M.); (T.L.N.); (J.F.H.)
- Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (C.S.); (L.V.); (D.S.)
| | - Brian Hutton
- Clinical Epidemiology Program, The Ottawa Hospital Research Institute, The University of Ottawa, Ottawa, ON K1H 8L6, Canada; (D.F.); (B.H.)
| | - Mark Clemons
- Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, The University of Ottawa, Ottawa, ON K1H 8L6, Canada; (S.D.); (A.A.A.); (S.F.M.); (T.L.N.); (J.F.H.)
- Cancer Therapeutics Program, The Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada; (C.S.); (L.V.); (D.S.)
| |
Collapse
|
5
|
Clemons M, Fergusson D, Joy AA, Thavorn K, Meza-Junco J, Hiller JP, Mackey J, Ng T, Zhu X, Ibrahim MFK, Sienkiewicz M, Saunders D, Vandermeer L, Pond G, Basulaiman B, Awan A, Pitre L, Nixon NA, Hutton B, Hilton JF. A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. Breast 2021; 58:42-49. [PMID: 33901921 PMCID: PMC8095051 DOI: 10.1016/j.breast.2021.03.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 03/23/2021] [Accepted: 03/29/2021] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetaxel-cyclophosphamide (TC) chemotherapy for early-stage breast cancer (EBC). A pragmatic randomised trial compared the superiority of G-CSF to ciprofloxacin and a cost-utility analysis were conducted. METHODS EBC patients receiving TC chemotherapy were randomised to ciprofloxacin or G-CSF. The primary outcome was a composite of FN and non-FN treatment-related hospitalisation. Secondary outcomes included; rates of FN, non-FN treatment-related hospitalisation, chemotherapy dose reductions/delays/discontinuations. Primary analysis was performed with the intention to treat population. Cost-utility analyses were conducted from the Canadian public payer perspective. RESULTS 458 eligible patients were randomised: 228 to ciprofloxacin and 230 to G-CSF. For the primary endpoint there was non-statistically significant difference (Risk difference = -6.7%, 95%CI = -13.5%-0.1%, p = 0.061) between ciprofloxacin patients (46,20.2%) and G-CSF (31,13.5%). Patients receiving ciprofloxacin were more likely to experience FN (36/228, 15.8% vs 13/230, 5.7%) than patients receiving G-CSF (p < 0.001). Non-FN treatment-related hospitalisation occurred in 40/228 (17.5%) of ciprofloxacin patients vs 28/230 (12.2%) of G-CSF patients (p = 0.12). There were no differences in other secondary outcomes. G-CSF was associated with an incremental cost-effectiveness ratio of C$1,760,796 per one quality-adjusted life year gained. CONCLUSION The primary endpoint of superiority of G-CSF over ciprofloxacin was not demonstrated. While there were reduced FN rates with G-CSF, there were no differences in chemotherapy dose delays/reductions or discontinuations. With the commonly used willingness to pay value of C$50,000/QALY, G-CSF use was not cost-effective compared to ciprofloxacin and deserves scrutiny from the payer perspective.
Collapse
Affiliation(s)
- Mark Clemons
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada; Clinical Epidemiology Program, Ottawa Hospital Research Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
| | - Dean Fergusson
- Clinical Epidemiology Program, Ottawa Hospital Research Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
| | - Anil A Joy
- Division of Medical Oncology, Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
| | - Kednapa Thavorn
- Clinical Epidemiology Program, Ottawa Hospital Research Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
| | - Judith Meza-Junco
- Division of Medical Oncology, Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
| | - Julie Price Hiller
- Division of Medical Oncology, Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
| | - John Mackey
- Division of Medical Oncology, Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
| | - Terry Ng
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada
| | - Xiaofu Zhu
- Division of Medical Oncology, Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
| | - Mohammed F K Ibrahim
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada
| | - Marta Sienkiewicz
- Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - Deanna Saunders
- Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - Lisa Vandermeer
- Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada
| | - Gregory Pond
- Department of Oncology, McMaster University, Hamilton, Canada
| | - Bassam Basulaiman
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada
| | - Arif Awan
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada
| | - Lacey Pitre
- Department of Oncology, Northeast Cancer Centre, Sudbury, Canada
| | - Nancy A Nixon
- Division of Medical Oncology, Department of Oncology, University of Alberta, Tom Baker Cancer Centre, Calgary, Canada
| | - Brian Hutton
- Clinical Epidemiology Program, Ottawa Hospital Research Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
| | - John F Hilton
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada
| |
Collapse
|
6
|
Hull JC, Bloch EM, Ingram C, Crookes R, Vaughan J, Courtney L, Jauregui A, Hilton JF, Murphy EL. Slower response to treatment of iron-deficiency anaemia in pregnant women infected with HIV: a prospective cohort study. BJOG 2021; 128:1674-1681. [PMID: 33587784 DOI: 10.1111/1471-0528.16671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/30/2021] [Indexed: 11/29/2022]
Abstract
OBJECTIVE Antenatal anaemia is associated with increased peripartum transfusion requirement in South Africa. We studied whether HIV was associated with the response to treatment of iron-deficiency anaemia. DESIGN Prospective cohort study. SETTING Hospital-based antenatal anaemia clinic in South Africa. SAMPLE Equal-sized cohorts of pregnant women testing positive for HIV (HIV+) and testing negative for HIV (HIV-) with iron-deficiency anaemia. METHODS Haemoglobin trajectories of women with confirmed iron-deficiency anaemia (ferritin < 50 ng/ml) were estimated from the initiation of iron supplementation using mixed-effects modelling, adjusted for baseline HIV status, ferritin level, maternal and gestational ages and time-varying iron supplementation. MAIN OUTCOME MEASURES Haemoglobin trajectories. RESULTS Of 469 women enrolled, 51% were HIV+, 90% of whom were on antiretroviral therapy (with a mean CD4+ lymphocyte count of 403 cells/mm3 ). Anaemia diagnoses did not differ by HIV status. A total of 400 women with iron-deficiency anaemia were followed during treatment with oral or intravenous (6%) iron therapy. In multivariable analysis, haemoglobin recovery was 0.10 g/dl per week slower on average in women who were HIV+ versus women who were HIV- (P = 0.001), 0.01 g/dl per week slower in women with higher baseline ferritin (P < 0.001) and 0.06 g/dl per week faster in women who were compliant with oral iron therapy (P = 0.002). CONCLUSIONS Compared with women who were HIV-, women who were HIV+ with iron-deficiency anaemia had slower but successful haemoglobin recovery with iron therapy. Earlier effective management of iron deficiency could reduce the incidence of peripartum blood transfusion. TWEETABLE ABSTRACT Among pregnant women with iron-deficiency anaemia in South Africa, HIV slows haemoglobin recovery in response to oral iron therapy.
Collapse
Affiliation(s)
- J C Hull
- Chris Hani Baragwanath Academic Hospital, Soweto, South Africa.,University of the Witwatersrand, Johannesburg, South Africa
| | - E M Bloch
- Johns Hopkins University School of Medicine, Baltimore, MA, USA
| | - C Ingram
- National Bone Marrow Registry, Cape Town, South Africa
| | - R Crookes
- Cryo-Save Inc., Johannesburg, South Africa
| | - J Vaughan
- National Health Laboratory Services, CH Baragwanath Hospital, Soweto, South Africa.,Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa
| | | | - A Jauregui
- Stanford University School of Medicine, Stanford, CA, USA
| | - J F Hilton
- University of California San Francisco (UCSF), San Francisco, CA, USA
| | - E L Murphy
- University of California San Francisco (UCSF), San Francisco, CA, USA.,Vitalant Research Institute (VRI), San Francisco, CA, USA
| | | |
Collapse
|
7
|
Kendzerska T, Povitz M, Leung RS, Boulos MI, McIsaac DI, Murray BJ, Bryson GL, Talarico R, Hilton JF, Malhotra A, Gershon AS. Obstructive Sleep Apnea and Incident Cancer: A Large Retrospective Multicenter Clinical Cohort Study. Cancer Epidemiol Biomarkers Prev 2020; 30:295-304. [PMID: 33268490 DOI: 10.1158/1055-9965.epi-20-0975] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 10/01/2020] [Accepted: 11/20/2020] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND To examine the association between the severity of obstructive sleep apnea (OSA) and nocturnal hypoxemia with incident cancer. METHODS This was a multicenter retrospective clinical cohort study using linked clinical and provincial health administrative data on consecutive adults who underwent a diagnostic sleep study between 1994 and 2017 in four academic hospitals (Canada) who were free of cancer at baseline. Cancer status was derived from the Ontario Cancer Registry. Cox cause-specific regressions were utilized to address the objective and to calculate the 10-year absolute risk difference (ARD) in the marginal probability of incident cancer and the number needed to harm (NNH). RESULTS Of 33,997 individuals considered, 33,711 with no missing OSA severity were included: median age, 50 years; 58% male; and 23% with severe OSA (apnea-hypopnea index >30). Of the 18,458 individuals with information on sleep time spent with oxygen saturation (SaO2) <90%, 5% spent >30% of sleep with SaO2 <90% (severe nocturnal hypoxemia). Over a median of 7 years, 2,498 of 33,711 (7%) individuals developed cancer, with an incidence rate of 10.3 (10.0-10.8) per 1,000 person-years. Controlling for confounders, severe OSA was associated with a 15% increased hazard of developing cancer compared with no OSA (HR = 1.15, 1.02-1.30; ARD = 1.28%, 0.20-2.37; and NNH = 78). Severe hypoxemia was associated with about 30% increased hazard (HR = 1.32, 1.08-1.61; ARD = 2.38%, 0.47-4.31; and NNH = 42). CONCLUSIONS In a large cohort of individuals with suspected OSA free of cancer at baseline, the severity of OSA and nocturnal hypoxemia was independently associated with incident cancer. IMPACT These findings suggest the need for more targeted cancer risk awareness in individuals with OSA.
Collapse
Affiliation(s)
- Tetyana Kendzerska
- Department of Medicine, The Ottawa Hospital/University of Ottawa, Ottawa, Ontario, Canada.
- ICES (formerly the Institute for Clinical Evaluative Sciences), Ottawa, Toronto, Ontario, Canada
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Marcus Povitz
- Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
| | - Richard S Leung
- Department of Medicine, the University of Toronto, Toronto, Ontario, Canada
- St. Michael's Hospital, Toronto, Ontario, Canada
| | - Mark I Boulos
- Department of Medicine, the University of Toronto, Toronto, Ontario, Canada
- Division of Neurology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Daniel I McIsaac
- ICES (formerly the Institute for Clinical Evaluative Sciences), Ottawa, Toronto, Ontario, Canada
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- Departments of Anesthesiology and Pain Medicine, The Ottawa Hospital/University of Ottawa, Ottawa, Ontario, Canada
| | - Brian J Murray
- Department of Medicine, the University of Toronto, Toronto, Ontario, Canada
- Division of Neurology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - Gregory L Bryson
- Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
- Departments of Anesthesiology and Pain Medicine, The Ottawa Hospital/University of Ottawa, Ottawa, Ontario, Canada
| | - Robert Talarico
- ICES (formerly the Institute for Clinical Evaluative Sciences), Ottawa, Toronto, Ontario, Canada
| | - John F Hilton
- Department of Medicine, The Ottawa Hospital/University of Ottawa, Ottawa, Ontario, Canada
| | - Atul Malhotra
- Department of Medicine, the University of California, San Diego, California
| | - Andrea S Gershon
- ICES (formerly the Institute for Clinical Evaluative Sciences), Ottawa, Toronto, Ontario, Canada
- Department of Medicine, the University of Toronto, Toronto, Ontario, Canada
- Division of Respirology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| |
Collapse
|
8
|
Stewart DJ, Bosse D, Robinson A, Ong M, Fung-Kee-Fung M, Brule S, Hilton JF, Ocana A. Potential insights from population kinetic assessment of progression-free survival curves. Crit Rev Oncol Hematol 2020; 153:103039. [PMID: 32622319 DOI: 10.1016/j.critrevonc.2020.103039] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 06/23/2020] [Accepted: 06/23/2020] [Indexed: 12/26/2022] Open
Abstract
Progression-free survival (PFS) curves follow first order kinetics on exponential decay nonlinear regression analysis (EDNLRA). Some exhibit 1-phase-decay, some have 2-phase-decay, some are convex. We digitized, performed EDNLRA and generated log-linear plots for 887 published PFS curves for incurable solid tumors treated with various systemic therapies. Proportion of curves fitting 2-phase-decay varied by therapy (p < 0.0001). For 13 therapies, >64 % of PFS curves had 2-phase-decay. This included epidermal growth factor receptor inhibitors in unselected lung cancer patients (some with, some without mutations), immune checkpoint inhibitors, interferon, breast cancer hormonal therapies, and selected others, suggesting 2 distinct, potentially identifiable subpopulations with differing progression rates. For 22 other therapies, <25 % of PFS curves had 2-phase-decay. Only 1 therapy was in the mid-range. Small cell lung and colon carcinomas were particularly likely to yield highly convex curves (p < 0.006), probably from discontinuation of effective therapies. PFS curve shape may yield biological and clinical insights.
Collapse
Affiliation(s)
| | | | | | - Michael Ong
- University of Ottawa, Ottawa, ON, United States
| | | | | | | | - Alberto Ocana
- Experimental Therapeutics Unit, Hospital Clínico San Carlos, and CIBERONC, Madrid, Spain
| |
Collapse
|
9
|
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SRD, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol 2020; 21:763-775. [DOI: 10.1016/s1470-2045(20)30112-1] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 02/10/2020] [Accepted: 02/13/2020] [Indexed: 12/15/2022]
|
10
|
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SRD, Chan A, Goel S, Catron K, Yang Z, Gianford MC, Price GL, André F. Abstract P3-11-10: Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p3-11-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Abemaciclib is an oral selective inhibitor of cyclin-dependent kinases 4 and 6 approved for hormone receptor (HR)+, human epidermal growth factor receptor 2 (HER2)- metastatic breast cancer. In the randomized, 3-arm, phase 2 study monarcHER (NCT02675231) for HR+, HER2+ advanced breast cancer (ABC), abemaciclib in combination with trastuzumab (T) and fulvestrant (F) significantly improved investigator-assessed progression-free survival (whereas abemaciclib + T did not) versus (vs) T + physician’s choice of chemotherapy and demonstrated a tolerable safety profile. Here, patient-reported HRQoL, functioning, and symptoms are reported.
Methods: In monarcHER, 237 postmenopausal (surgical, natural, or chemical ovarian suppression) women with ABC and ≥2 prior HER2+ directed therapies in the advanced setting were randomized 1:1:1 to abemaciclib (150 mg PO Q12H every 21 days) + T (IV infusion on D1 every 21 days) with F (500 mg IM on Cycle 1 D1 and D15 and Cycle 2 D8, then Q4W; Arm A) or without F (Arm B) vs T + physician’s choice of chemotherapy (per label every 21 days; Arm C). Supportive measures to manage diarrhea were permitted. Patient-reported outcomes were measured at baseline and at each cycle using the modified Brief Pain Inventory-short form (mBPI-sf) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). The EuroQol 5-Dimension 5 Level (EQ-5D 5L) questionnaire was also collected. Higher scores on EORTC QLQ-C30 functional and health status/QoL scales indicate improvement whereas higher scores on EORTC QLQ-C30 symptom scales and mBPI-sf indicate worsening of symptoms/pain. The EQ-5D 5L index score was calculated from a set of item weights to derive a score of 0-1, with 1 representing the best health status. Treatment arm comparisons of change from baseline (all post-baseline visits) were conducted using a mixed model repeated measure, with .05 considered statistically significant. Clinical meaningfulness was defined as a ≥10-point score change from baseline (on a 0-100 scale) for EORTC QLQ-C30 and a 2-point score change from baseline for mBPI-sf.
Results: Patient-reported outcome compliance rates were ≥90% through Cycle 15; the range for median duration of each treatment component of each arm was 7.5-10.0 cycles. Overall, no statistically significant or clinically meaningful changes from baseline differences were observed between treatment arms for mBPI-sf pain scores or EORTC QLQ-C30 global health score, function scales, or for symptoms of fatigue, dyspnea, appetite loss, or financial difficulties. Least square (LS) mean change from baseline differences showed statistically significant improvements in Arm A vs C for EORTC QLQ-C30 symptoms of pain (-6.81; p=.026) and insomnia (-6.39; p=.041). Worsening for the symptom of nausea/vomiting was statistically significant but not clinically meaningful in Arm A vs C (4.08; p=.043). Diarrhea showed a statistically significant and clinically meaningful worsening in Arm A vs C (19.27; p<.001). A by-cycle analysis showed mean nausea/vomiting and diarrhea symptom scores were generally higher during earlier visits and returned to near-baseline levels after treatment discontinuation. The EQ-5D 5L index score improved in Arm A vs C, with an LS mean change from baseline difference of .05 (p=.033).
Conclusions: Quality of life was maintained for patient-reported pain, global health, functioning, and most symptoms when abemaciclib was added to T + F compared with physician’s choice of chemotherapy in patients with HR+, HER2+ ABC. Gastrointestinal-related symptoms were transient and consistent with the manageable, reversible adverse event profile.
Citation Format: Sara M Tolaney, Andrew M Wardley, Stefania Zambelli, John F. Hilton, Tiffany A Troso-Sandoval, Francesco Ricci, Seock-Ah Im, Sung-Bae Kim, Stephen RD Johnston, Arlene Chan, Shom Goel, Kristen Catron, Zhengyu Yang, M. Corona Gianford, Gregory L Price, Fabrice André. Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-11-10.
Collapse
Affiliation(s)
| | - Andrew M Wardley
- 2NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust & Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine & Health, University of Manchester, Manchester, United Kingdom
| | | | - John F. Hilton
- 4The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada
| | | | | | - Seock-Ah Im
- 7Seoul National University College of Medicine, Seoul, Korea, Republic of
| | - Sung-Bae Kim
- 8Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
| | | | - Arlene Chan
- 10Breast Cancer Research Centre - WA and Curtin University, Nedlands, Australia
| | - Shom Goel
- 1Dana-Farber Cancer Institute, Boston, MA
| | | | | | | | | | - Fabrice André
- 12Gustave Roussy, Université Paris Sud, INSERM, Villejuif, France
| |
Collapse
|
11
|
Stewart DJ, Bossé D, Goss G, Hilton JF, Jonker D, Fung-Kee-Fung M. A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model. Crit Rev Oncol Hematol 2020; 148:102896. [PMID: 32087510 DOI: 10.1016/j.critrevonc.2020.102896] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2019] [Revised: 01/16/2020] [Accepted: 01/29/2020] [Indexed: 02/09/2023] Open
Abstract
Progression-free survival (PFS) hazard ratios and gain in median PFS are suggested predictors of overall survival (OS) gain (with gain defined as experimental arm minus control arm values). We assessed use of half-lives (time to progression/death of half remaining patients). We reviewed randomized trials from Journal of Clinical Oncology and New England Journal of Medicine, 01/2012-06/12/2017 (discovery series) and 01/01/2007-12/31/2011 (first validation series). If PFS or OS gains were significant, we used PFS/OS curve nonlinear regression analysis to estimate half-lives and defined "half-life gain" as experimental minus control arm half-life. With low crossover and significant PFS differences, PFS half-life gains ≥1.5 months had positive-predictive-values for OS gains ≥2 months of 79 % and 86 % and PFS half-life gains <1.5 months had negative-predictive-values for OS gains <2 months of 95 % and 75 %, in discovery and validation series, respectively. PFS half-life gains more reliably predicted OS gains than PFS hazard ratios or gains in median PFS. Findings were confirmed in a second validation series.
Collapse
Affiliation(s)
- David J Stewart
- University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
| | - Dominick Bossé
- University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
| | - Glenwood Goss
- University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
| | - John F Hilton
- University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
| | - Derek Jonker
- University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
| | - Michael Fung-Kee-Fung
- University of Ottawa and the Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
| |
Collapse
|
12
|
Clemons M, Mazzarello S, Pond G, Amir E, Asmis T, Berry S, Brackstone M, Brule S, Goodwin R, Hilton JF, Julião M, Nicholas G, Stewart DJ, Wheatley-Price P, Cholmsky L, Krentel A, Hutton B, Joy AA. A prospective intervention to improve happiness and reduce burnout in oncologists. Support Care Cancer 2018; 27:1563-1572. [PMID: 30506102 DOI: 10.1007/s00520-018-4567-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2018] [Accepted: 11/20/2018] [Indexed: 11/25/2022]
Abstract
BACKGROUND There is a paucity of data about effective interventions to improve happiness and reduce burnout in oncologists. Benjamin Franklin developed a 13-week program of "necessary activities" or "virtues" (temperance, silence, order, resolution, frugality, industry, sincerity, justice, moderation, cleanliness, tranquility, chastity, and humility) to follow, in his attempt at self-improvement. In this pilot study, we explored whether using a modified version of this was associated with any discernable impact on physician happiness, burnout, or compliance with each of the virtues. METHODS Self-reported happiness (Oxford happiness scores) and burnout (Abbreviated Maslach Burnout Inventory) were completed at baseline (pre-study), week 13, and 1 month after completion of the program. Each day during the 13-week program, oncologists were emailed a list of virtues to focus on and scored how they felt they were complying with them. The oncologist's spouses also assessed how they felt the oncologist was complying with the virtues. RESULTS Thirteen physicians completed the baseline scores, 11 completed Maslach/Oxford scores at the end of the study, and 8 the 1-month post-study assessment. No significant improvements in happiness and burnout (emotional exhaustion, depersonalization, personal accomplishment) scores were observed. Statistically significant changes in self-rated virtue scores were observed for temperance (p = 0.046), order (p = 0.049), and resolution (p = 0.014). Additionally, although not reaching statistical significance, 11 of 13 virtues (excepting sincerity and chastity) assessed by spouses indicated a positive change over time. CONCLUSION In this hypothesis generating study, daily reflection on personal virtues was not associated with any statistically significant change in happiness or burnout scores. Alternative strategies should be considered.
Collapse
Affiliation(s)
- Mark Clemons
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada.
- Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada.
| | - Sasha Mazzarello
- Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada
- Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada
| | - Gregory Pond
- Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada
| | - Eitan Amir
- Princess Margaret Cancer Centre, Toronto, Canada
| | - Timothy Asmis
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada
- Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada
| | - Scott Berry
- Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada
| | | | - Stephanie Brule
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada
| | - Rachel Goodwin
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada
| | - John F Hilton
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada
- Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada
| | - Miguel Julião
- Equipa Comunitária de Suporte em Cuidados Paliativos ACES Sintra, Sintra, Portugal
| | - Garth Nicholas
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada
| | - David J Stewart
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada
- Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada
| | - Paul Wheatley-Price
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, 501 Smyth Road, Box 912, Ottawa, ON, K1H 8L6, Canada
- Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada
| | - Laurel Cholmsky
- Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada
| | | | - Brian Hutton
- Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada
- Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada
| | - Anil A Joy
- Division of Medical Oncology, Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
| |
Collapse
|
13
|
Basulaiman B, Awan A, Hilton JF, Clemons M. Conflict of interest: "Be rigorous in judging ourselves and gracious in judging others". ACTA ACUST UNITED AC 2018; 25:355-357. [PMID: 30607108 DOI: 10.3747/co.25.4587] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The recent New York Times article with the banner headline Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals and the subsequent discussion about Dr. Jose Baselga [...]
Collapse
Affiliation(s)
- B Basulaiman
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, ON
| | - A Awan
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, ON
| | - J F Hilton
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, ON.,Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON
| | - M Clemons
- Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, ON.,Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON
| |
Collapse
|
14
|
Hilton JF, Clemons M, Pond G, Zhao H, Mazzarello S, Vandermeer L, Addison CL. Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer. J Bone Oncol 2017; 10:6-13. [PMID: 29204337 PMCID: PMC5709351 DOI: 10.1016/j.jbo.2017.11.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Revised: 11/02/2017] [Accepted: 11/04/2017] [Indexed: 02/02/2023] Open
Abstract
Background Switching patients who remain at high risk of skeletal related events (SREs) despite pamidronate to the more potent bisphosphonate zoledronate, may be an effective treatment strategy. As part of a previously reported clinic study in this setting, we evaluated whether biomarkers for bone resorption, such as Bone-Specific Alkaline Phosphatase (BSAP), bone sialoprotein (BSP), and N-terminal telopeptide (NTX) correlated with subsequent SRE risk. Methods Breast cancer patients who remained at high risk of SREs despite at least 3 months of q.3–4 weekly pamidronate were randomized to either continue on pamidronate or to switch to zoledronate (4 mg) once every 4 weeks for 12-weeks. High risk bone metastases were defined by either: occurrence of a prior SRE, bone pain, radiologic progression of bone metastases and/or serum C-terminal telopeptide (CTx) levels > 400 ng/L despite pamidronate use. Serum samples were collected at baseline and weeks 1, 4, 8 and 12 (CTx and BSAP) and baseline and week 12 (NTx and BSP), and all putative biomarkers were measured by ELISA. Follow up was extended to 2 years post trial entry for risk of subsequent SREs. The Kaplan-Meier method was used to estimate time-to-event outcomes. Generalized estimating equations (GEE) were used to evaluate if laboratory values over time or the change in laboratory values from baseline were associated with having a SRE within the time frame of this study. Results From March 2012 to May 2014, 76 patients were screened, with 73 eligible for enrolment. All 73 patients were available for biochemical analysis, with 35 patients receiving pamidronate and 38 patients receiving zoledronate. The GEE analysis found that no laboratory value was associated with having a subsequent SRE. Interaction between visit and laboratory values was also investigated, but no interaction effect was statistically significant. Only increased number of lines of prior hormonal treatment was associated with subsequent SRE risk. Conclusion Our analysis failed to find any association between serum BSAP, BSP, CTx or NTx levels and subsequent SRE risk in this cohort of patients. This lack of correlation between serum biomarkers and clinical outcomes could be due to influences of prior bisphosphonate treatment or presence of extra-osseous metastases in a significant proportion of enrolled patients. As such, caution should be used in biomarker interpretation and use to direct decision making regarding SRE risk for high risk patients in this setting.
Collapse
Affiliation(s)
- J F Hilton
- Division of Medical Oncology and Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
| | - M Clemons
- Division of Medical Oncology and Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.,Ottawa Hospital Research Institute and University of Ottawa, Department of Medicine, Ottawa, Ontario, Canada
| | - G Pond
- Department of Oncology, McMaster University, Hamilton, ON, Canada
| | - H Zhao
- Ottawa Hospital Research Institute and University of Ottawa, Department of Medicine, Ottawa, Ontario, Canada
| | - S Mazzarello
- Ottawa Hospital Research Institute and University of Ottawa, Department of Medicine, Ottawa, Ontario, Canada
| | - L Vandermeer
- Ottawa Hospital Research Institute and University of Ottawa, Department of Medicine, Ottawa, Ontario, Canada
| | - C L Addison
- Ottawa Hospital Research Institute and University of Ottawa, Department of Medicine, Ottawa, Ontario, Canada
| |
Collapse
|
15
|
Shapiro GI, Do KT, Tolaney SM, Hilton JF, Cleary JM, Wolanski A, Beardslee B, Hassinger F, Bhushan K, Cai D, Downey E, Pruitt-Thompson S, Barry SM, Kochupurakkal B, Geradts J, Unitt C, D'Andrea AD, Muzikansky A, Piekarz R, Doyle LA, Supko J. Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-ct047] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Although PARP inhibition is effective against HR repair-deficient cancers, efficacy is limited by HR proficiency, whether present de novo or as a result of acquired resistance, prompting HR disrupting strategies to sensitize tumor cells. Inhibition of CDK1 and CDK12 compromise HR by blocking BRCA1 phosphorylation, affecting recruitment to sites of DNA damage, and by reducing HR gene expression, respectively. Dinaciclib is a pan-CDK inhibitor that inhibits both CDK1 and CDK12 at nanomolar potency. We conducted a Phase 1 study combining dinaciclib and veliparib in patients with advanced solid tumors who are not germline BRCA carriers. Methods: A 3+3 design was utilized. Veliparib was administered twice daily continuously in 28-day cycles. Dinaciclib was administered intravenously on days 8 and 22. In part 1A, escalation followed a two-dimensional schema, utilizing doses of dinaciclib between 10 - 45 mg/m2 and veliparib between 20 - 120 mg. In part 1B, veliparib was escalated between 200 mg - 400 mg with dinaciclib maintained at 30 mg/m2. PK and PD assessments were performed at baseline, after veliparib, and after the combination. Preliminary Results: Sixty-three heavily pretreated patients were enrolled in part 1A (n = 39) and 1B (n = 24). Thirty-four patients had breast or gynecologic malignancies. The MTD was 400 mg twice-daily veliparib with dinaciclib at 30 mg/m2. DLTs included G4 neutropenia > 7 days (n =1), febrile neutropenia (n = 1), mucositis (n = 1) and fatigue (n = 1). Common drug-related toxicities were neutropenia (78%), nausea (75%), fatigue (67%), electrolyte abnormalities (59%), elevated liver function tests (57%), diarrhea (52%), lymphopenia (52%), anemia (43%), dehydration (37%), anorexia (30%), vomiting (29%), hypoalbuminemia (29%), dizziness (29%), headache (22%), mucositis (18%), elevated creatinine (16%), alopecia (16%), thrombocytopenia (14%), abdominal pain (13%), insomnia (13%), and dysgeusia (11%). The median number of cycles completed was 2 (r: 1 - 10). One patient with TNBC achieved complete resolution of axillary adenopathy lasting > 8 months. Twenty-four patients (38%) had stable disease as the best response, with 9 progression-free > 4 months (TNBC, gynecologic and thymic ca). Paired tumor biopsies from one patient demonstrated reduced Ki-67 and increased gamma-H2AX staining after combination treatment compared to after veliparib alone. Conclusions: Dinaciclib administered at doses known to produce PD effects is tolerable with full dose veliparib. Anti-tumor activity is limited in non-BRCA carriers, possibly related to intermittent administration of a CDK inhibitor with known short half-life. Additional patients are being enrolled utilizing dinaciclib in more dose-intense schedules.
Citation Format: Geoffrey I. Shapiro, Khanh T. Do, Sara M. Tolaney, John F. Hilton, James M. Cleary, Andrew Wolanski, Brian Beardslee, Faith Hassinger, Ketki Bhushan, Dongpo Cai, Elizabeth Downey, Solida Pruitt-Thompson, Suzanne M. Barry, Bose Kochupurakkal, Joseph Geradts, Christine Unitt, Alan D. D'Andrea, Alona Muzikansky, Richard Piekarz, L. Austin Doyle, Jeffrey Supko. Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT047. doi:10.1158/1538-7445.AM2017-CT047
Collapse
|
16
|
Stewart DJ, Bosse D, Brule S, Robinson AG, Ong M, Hilton JF. Abstract 1774: Progression-free survival curves suggest a dichotomous determinant of PD-L1 inhibitor efficacy. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-1774] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PD-L1 expression varies across tumors but does not accurately predict PD-L1 inhibitor efficacy. Some negative tumors respond and some positive tumors fail. PD-L1 inhibitor progression-free survival (PFS) curve shape in non-small cell lung cancer (NSCLC) suggests that a dichotomous (present vs absent) factor might drive sensitivity rather than it being driven by a continuous variable like PD-L1 expression. PFS curves may follow first order kinetics, with a straight line if log % PFS is plotted vs time. If the population had 2 distinct subgroups with differing rates of progression then one would expect an inflection point on the log-linear curve, and the curve would fit a 2-phase decay model in nonlinear regression analysis (NLRA). A more homogeneous population would not fit a 2-phase model.
Methods: We used arohatgi.info/WebPlotDigitizer/app/ to digitize published PFS curves, then GraphPad Prism5 for 2-phase NLRA, with the constraints Y0=100, plateau=0. To generate standardized 2-phase curves, we utilized 1) unselected NSCLC patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) where we expected a high proportion of curves to fit a 2-phase model as only some patients would have a sensitizing EGFR mutation; 2) NSCLC EGFR mutant and wild type (WT) patients treated with EGFR TKIs, and patients treated with platinum-based chemotherapy, taxanes or placebo/best supportive care (BSC), where we expected a lower proportion of curves to fit 2-phase models; 3) PD-L1 PFS curves in NSCLC and other tumor types.
Results: With EGFR TKIs in unselected patients, 58 of 79 (73%) curves were fit by 2-phase models, vs 5 of 37 (14%) with EGFR TKIs in EGFR mutant patients (p<0.0001), 13 of 27 (48%) in EGFR WT patients (p<0.02), 4 of 37 (11%) with platinum-based therapy (p<0.0001), 15 of 47 (32%) with a taxane (p<0.0001), and 6 of 22 (27%) with placebo/BSC (p=0.0001). With PD-L1 inhibitors in NSCLC, 30 of 32 (94%) curves fit 2-phase models (p<0.0001 vs each of EGFR TKIs in EGFR mutants, EGFR WTs, platinum and taxane chemotherapy and placebo/BSC). In other tumor types, 27 of 32 (84%) PD-L1 curves fit 2-phase models.
Conclusions: Most PD-L1 inhibitor PFS curves fit a 2-phase model. This is similar to what we observed with EGFR TKIs in unselected patients and different from EGFR TKIs in EGFR mutant and WT patients, and from chemotherapy or placebo/BSC. This leads us to hypothesize the existence of a dichotomous (present vs absent) factor such as a gene mutation, deletion or silencing that sensitizes tumors to PD-1/PD-L1 inhibitors. If found, such a dichotomous factor could prove to be a highly useful biomarker that could permit accurate prediction of PD-1/PD-L1 inhibitor efficacy. Since PD-1/PD-L1 inhibitor efficacy is higher in tumors with high PD-L1 expression, any sensitizing dichotomous factor might also drive PD-L1 expression.
Citation Format: David J. Stewart, Dominick Bosse, Stephanie Brule, Andrew G. Robinson, Michael Ong, John F. Hilton. Progression-free survival curves suggest a dichotomous determinant of PD-L1 inhibitor efficacy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1774. doi:10.1158/1538-7445.AM2017-1774
Collapse
Affiliation(s)
| | | | | | | | - Michael Ong
- 1University of Ottawa, Ottawa, Ontario, Canada
| | | |
Collapse
|
17
|
Abramson VG, Supko JG, Ballinger T, Cleary JM, Hilton JF, Tolaney SM, Chau NG, Cho DC, Pearlberg J, Lager J, Shapiro GI, Arteaga CL. Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. Clin Cancer Res 2016; 23:3520-3528. [PMID: 28031425 DOI: 10.1158/1078-0432.ccr-16-1764] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Revised: 12/05/2016] [Accepted: 12/14/2016] [Indexed: 11/16/2022]
Abstract
Purpose: This phase Ib study was designed to determine the MTD, safety, preliminary efficacy, and pharmacokinetics of the HER3 (ErbB3) mAb SAR256212 in combination with the oral PI3K inhibitor SAR245408 for patients with metastatic or locally advanced solid tumors.Experimental Design: Patients received the combination of intravenous SAR256212 and oral SAR245408 in a 3 + 3 dose-escalation design until occurrence of disease progression or dose-limiting toxicity. Objective response rate, pharmacokinetics, pharmacodynamics, and PIK3CA mutational status were also evaluated.Results: Twenty-seven patients were enrolled. Thirteen of 20 patients tested (65%) had a hotspot-activating mutation in PIK3CA in their tumor. The MTD was determined to be SAR256212 at 40 mg/kg loading dose followed by 20 mg/kg weekly, plus SAR245408 200 mg daily. Dose-limiting toxicities included rash and hypotension; the most frequent treatment-related side effect was diarrhea (66.7%). Twenty-three patients were evaluable for efficacy, of which 12 patients (52.2%) had stable disease and 11 patients (47.8%) had progression of disease as best response. In this study with a limited sample size, there was no difference in best response between patients with PI3KCA-mutant versus PIK3CA wild-type tumors (P = 0.07). The concurrent administration of SAR245408 and SAR256212 did not appear to have an effect on the pharmacokinetics of either drug.Conclusions: The combination of SAR256212 and SAR245408 resulted in stable disease as the best response. Side effects seen in combination were similar to the profiles of each individual drug. Patient outcome was the same regardless of tumor PI3KCA mutation status. Clin Cancer Res; 23(14); 3520-8. ©2016 AACR.
Collapse
Affiliation(s)
- Vandana G Abramson
- Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.,Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Jeffrey G Supko
- Clinical Pharmacology Laboratory, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts
| | - Tarah Ballinger
- Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| | - James M Cleary
- Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.,Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - John F Hilton
- Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.,Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Sara M Tolaney
- Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.,Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.,Breast Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Nicole G Chau
- Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.,Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Daniel C Cho
- Division of Hematology and Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
| | | | | | - Geoffrey I Shapiro
- Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. .,Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Carlos L Arteaga
- Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee. .,Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
| |
Collapse
|
18
|
Paweletz CP, Oxnard GR, Feeney N, Hilton JF, Gandhi L, Do KT, Anderson A, Wolanski A, Tejeda A, English JM, Kirschmeier PT, Jänne PA, Shapiro GI. Abstract 3157: Serial droplet digital PCR (ddPCR) of plasma cell-free DNA (cfDNA) as pharmacodynamic (PD) biomarker in Phase 1 clinical trials for patients (pts) with KRAS mutant non-small cell lung cancer (NSCLC). Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-3157] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Phase 1 clinical trials of novel therapeutics have historically focused on toxicity, but increasingly are doubling as efficacy studies in biomarker-enriched populations. Given the small sample sizes (∼3-6 patients per dose), response on imaging may be a coarse marker of therapeutic effect. Here we piloted serial ddPCR of plasma cfDNA as a PD marker in a phase I combination study of a MEK inhibitor and a CDK 4/6 inhibitor in patients with RAS mutated cancers.
Methods / Results: Twenty-five pts with RAS-mutated cancer (incl. 17 patients with KRAS-mutant NSCLC) have been enrolled to date in a phase I dose escalation trial of the MEK inhibitor PD-0325901 with the CDK4/6 inhibitor palbociclib (NCT02022982). Plasma for cfDNA genotyping was collected at baseline prior to therapy and at the beginning of cycle 2. Plasma genotyping for KRAS G12X mutations was performed using a validated and highly quantitative droplet digital PCR assay.
Pts were enrolled in 5 dose level cohorts ranging from 75 mg palbociclib daily (3 weeks on, 1 week off) with 2 mg PD-0325901 BID (3 weeks on 1week off) to 125 mg palbociclib daily with 8 mg PD-0325901 BID (Table). KRAS mutations were detected in 14/24 pts at baseline (59%, median 1402 copies/mL plasma, range: 11-93000), consistent with the previously reported sensitivity of 64%. A second blood draw at cycle 2 was obtained for all 14 pts. A positive plasma response, defined as decrease of KRAS G12X mutants from first to second dose, was observed in 6 pts (range -6% - -100%) with the most plasma responders (n = 4 pts) at the maximum administered dose. At lower administered doses, there was a median increase in plasma KRAS mutant levels.
Conclusions: Increasing dose levels resulted in more consistent decreases in KRAS mutation in cfDNA, consistent with a dose-dependent pharmacodynamic effect.These results highlight the potential value of serial plasma ddPCR as a PD marker in early phase clinical trials. Dose LevelPalbociclib (QD, 3 wks on 1 wk off) mgPD-0325901 (BID, 3 wks on 1 wk off) mgN Enrolled (N analyzed)Median Plasma change KRAS mut(%)17523 (1)+2427543 (3)+60 (range +31 - +150)310048 (4)+150 (range -6 - +341)412544 (2)+9 (range -45 - +61)512587 (4)-27 (range -7 - -43)
Citation Format: Cloud P. Paweletz, Geoffrey R. Oxnard, Nora Feeney, John F. Hilton, Leena Gandhi, Khanh T. Do, Adrienne Anderson, Andrew Wolanski, Alexander Tejeda, Jessie M. English, Paul T. Kirschmeier, Pasi A. Jänne, Geoffrey I. Shapiro. Serial droplet digital PCR (ddPCR) of plasma cell-free DNA (cfDNA) as pharmacodynamic (PD) biomarker in Phase 1 clinical trials for patients (pts) with KRAS mutant non-small cell lung cancer (NSCLC). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3157.
Collapse
|
19
|
Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discov 2016; 6:740-53. [PMID: 27217383 DOI: 10.1158/2159-8290.cd-16-0095] [Citation(s) in RCA: 504] [Impact Index Per Article: 63.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2016] [Accepted: 04/26/2016] [Indexed: 11/16/2022]
Abstract
UNLABELLED We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 and 6, in a multicenter study including phase I dose escalation followed by tumor-specific cohorts for breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, melanoma, and colorectal cancer. A total of 225 patients were enrolled: 33 in dose escalation and 192 in tumor-specific cohorts. Dose-limiting toxicity was grade 3 fatigue. The maximum tolerated dose was 200 mg every 12 hours. The most common possibly related treatment-emergent adverse events involved fatigue and the gastrointestinal, renal, or hematopoietic systems. Plasma concentrations increased with dose, and pharmacodynamic effects were observed in proliferating keratinocytes and tumors. Radiographic responses were achieved in previously treated patients with breast cancer, NSCLC, and melanoma. For hormone receptor-positive breast cancer, the overall response rate was 31%; moreover, 61% of patients achieved either response or stable disease lasting ≥6 months. SIGNIFICANCE Abemaciclib represents the first selective inhibitor of CDK4 and CDK6 with a safety profile allowing continuous dosing to achieve sustained target inhibition. This first-in-human experience demonstrates single-agent activity for patients with advanced breast cancer, NSCLC, and other solid tumors. Cancer Discov; 6(7); 740-53. ©2016 AACR.See related commentary by Lim et al., p. 697This article is highlighted in the In This Issue feature, p. 681.
Collapse
Affiliation(s)
- Amita Patnaik
- South Texas Accelerated Research Therapeutics, San Antonio, Texas.
| | - Lee S Rosen
- University of California, Los Angeles, California
| | | | | | | | - Leena Gandhi
- Dana-Farber Cancer Institute, Boston, Massachusetts
| | | | | | - Drew W Rasco
- South Texas Accelerated Research Therapeutics, San Antonio, Texas
| | | | - Aejaz Nasir
- Eli Lilly and Company, Indianapolis, Indiana
| | | | | | | | | | | | | | - Lily Q Li
- Eli Lilly and Company, Indianapolis, Indiana
| | | | | | | | | | | | | |
Collapse
|
20
|
Naseem M, Murray J, Hilton JF, Karamchandani J, Muradali D, Faragalla H, Polenz C, Han D, Bell DC, Brezden-Masley C. Mammographic microcalcifications and breast cancer tumorigenesis: a radiologic-pathologic analysis. BMC Cancer 2015; 15:307. [PMID: 25896922 PMCID: PMC4407616 DOI: 10.1186/s12885-015-1312-z] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2014] [Accepted: 02/20/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Microcalcifications (MCs) are tiny deposits of calcium in breast soft tissue. Approximately 30% of early invasive breast cancers have fine, granular MCs detectable on mammography; however, their significance in breast tumorigenesis is controversial. This study had two objectives: (1) to find associations between mammographic MCs and tumor pathology, and (2) to compare the diagnostic value of mammograms and breast biopsies in identifying malignant MCs. METHODS A retrospective chart review was performed for 937 women treated for breast cancer during 2000-2012 at St. Michael's Hospital. Demographic information (age and menopausal status), tumor pathology (size, histology, grade, nodal status and lymphovascular invasion), hormonal status (ER and PR), HER-2 over-expression and presence of MCs were collected. Chi-square tests were performed for categorical variables and t-tests were performed for continuous variables. All p-values less than 0.05 were considered statistically significant. RESULTS A total of 937 patient charts were included. About 38.3% of the patients presented with mammographic MCs on routine mammographic screening. Patients were more likely to have MCs if they were HER-2 positive (52.9%; p < 0.001). There was a significant association between MCs and peri-menopausal status with a mean age of 50 (64%; p = 0.012). Patients with invasive ductal carcinomas (40.9%; p = 0.001) were more likely to present with MCs than were patients with other tumor histologies. Patients with a heterogeneous breast density (p = 0.031) and multifocal breast disease (p = 0.044) were more likely to have MCs on mammograms. There was a positive correlation between MCs and tumor grade (p = 0.057), with grade III tumors presenting with the most MCs (41.3%). A total of 52.2% of MCs were missed on mammograms which were visible on pathology (p < 0.001). CONCLUSION This is the largest study suggesting the appearance of MCs on mammograms is strongly associated with HER-2 over-expression, invasive ductal carcinomas, peri-menopausal status, heterogeneous breast density and multifocal disease.
Collapse
Affiliation(s)
- Madiha Naseem
- Department of Hematology/Oncology, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario, M5B 1W8, Canada. .,Faculty of Medicine, University of Toronto, 1 Kings College Circle, Toronto, ON, M5S 1A8, Canada.
| | - Joshua Murray
- Horizon Health Network, The Moncton Hospital, 135 MacBeath Avenue, Moncton, New Brunswick, E1C 6Z8, Canada.
| | - John F Hilton
- Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.
| | - Jason Karamchandani
- Faculty of Medicine, University of Toronto, 1 Kings College Circle, Toronto, ON, M5S 1A8, Canada. .,Department of Laboratory Medicine and Pathology, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.
| | - Derek Muradali
- Faculty of Medicine, University of Toronto, 1 Kings College Circle, Toronto, ON, M5S 1A8, Canada. .,Department of Medical Imaging, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.
| | - Hala Faragalla
- Faculty of Medicine, University of Toronto, 1 Kings College Circle, Toronto, ON, M5S 1A8, Canada. .,Department of Laboratory Medicine and Pathology, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.
| | - Chanele Polenz
- Department of Hematology/Oncology, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario, M5B 1W8, Canada.
| | - Dolly Han
- Department of Hematology/Oncology, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario, M5B 1W8, Canada.
| | - David C Bell
- Department of Laboratory Medicine and Pathology, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.
| | - Christine Brezden-Masley
- Department of Hematology/Oncology, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario, M5B 1W8, Canada. .,Faculty of Medicine, University of Toronto, 1 Kings College Circle, Toronto, ON, M5S 1A8, Canada.
| |
Collapse
|
21
|
Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncol Lett 2014; 7:866-870. [PMID: 24527094 PMCID: PMC3919882 DOI: 10.3892/ol.2014.1782] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2013] [Accepted: 12/03/2013] [Indexed: 12/12/2022] Open
Abstract
Platinum-based chemotherapy regimens are frequently used in patients with triple-negative breast cancer (TNBC). The aim of the current study was to assess whether or not platinum-based chemotherapy is associated with an increased time to progression when compared with non-platinum-based regimens in TNBC and non-TNBC. A retrospective analysis was conducted within a cohort of patients with metastatic breast cancer who received platinum-based chemotherapy at a single institution. Data were collected for up to three lines of treatment for metastatic disease. Time to progression was determined for platinum-based chemotherapy and non-platinum-based regimens for each line of treatment. Adjusted hazard ratios (HRs), together with 95% confidence intervals (CIs) were estimated comparing the time to progression associated with the use of platinum-based chemotherapy versus non-platinum-based regimens. A total of 159 patients were included in the analysis, with 58 diagnosed with TNBC. Among the patients with TNBC, compared with non-platinum-based chemotherapy, no correlation was identified between platinum-based chemotherapy and an improved time to progression [first line: HR, 0.97 (95% CI, 0.40-2.35); second line: HR, 0.91 (95% CI, 0.42-2.01); and third line: HR, 2.83 (95% CI, 0.73-11.03)]. By contrast, patients with non-TNBC appeared to improve with non-platinum-based chemotherapy [first line: HR, 2.57 (95% CI, 1.11-5.99); second line: HR, 1.91 (95% CI, 1.00-3.63); and third line: HR, 1.08 (95% CI, 0.53-2.18)]. Although the present study was limited by the sample size and its observational nature, the results indicated that platinum-based chemotherapy does not offer a discernible or distinct advantage compared with standard regimens in patients with TNBC, and is perhaps less efficacious in patients with non-TNBC.
Collapse
Affiliation(s)
- Daniel Khalaf
- Division of Hematology-Oncology, University of Montreal - Notre-Dame Hospital, Montreal, QC H2L 4M1, Canada ; Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada
| | - John F Hilton
- Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada
| | - Mark Clemons
- Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada
| | - Laurent Azoulay
- Department of Oncology, Royal Victoria Hospital, McGill University, Montreal, QC H3A 1A1, Canada ; Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Hui Yin
- Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Lisa Vandermeer
- Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada
| | - Susan Dent
- Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada
| | - Sean Hopkins
- Department of Pharmacy, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada
| | - Nathaniel Bouganim
- Department of Oncology, Royal Victoria Hospital, McGill University, Montreal, QC H3A 1A1, Canada
| |
Collapse
|
22
|
Hilton JF, Bouganim N, Dong B, Chapman JW, Arnaout A, O'Malley F, Gelmon KA, Yerushalmi R, Levine MN, Bramwell VHC, Whelan TJ, Pritchard KI, Shepherd LE, Clemons M. Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials. Breast Cancer Res Treat 2013; 142:143-51. [PMID: 24113743 DOI: 10.1007/s10549-013-2714-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2013] [Accepted: 09/26/2013] [Indexed: 12/11/2022]
Abstract
The AJCC staging criteria consider tumor size to be the largest dimension of largest tumor. Some case series suggest using summation of all tumor dimensions in patients with multicentric/multifocal (MC/MF) disease. We used data from NCIC CTG MA.5 and MA.12 clinical trials to examine alternative methods of assessing tumor size on breast-cancer-free-interval (BCFI). The 710 MA.5 pre-/peri-menopausal node positive and 672 MA.12 pre-menopausal node-negative/-positive patients have 10-year median follow-up. All patients received adjuvant chemotherapy. Tumors were centrally reviewed for grade, hormone receptor, and HER2 status. Continuous pathologic tumor size was: (1) largest dimension of largest tumor (cm); (2) tumor area (cm(2)); (3) volume of tumor (cm(3)); (4) with MC/MF disease, summation of (1)-(3) for up to 3 foci. We examined univariate and multivariate effects of tumor size on BCFI utilizing (un)stratified Cox regression and the Wald test statistic. In univariate analysis, larger tumor dimension was significantly associated with worse BFCI in node positive patients: p < 0.0001 for MA.5; p = 0.01 for MA.12. In MA.5 multivariate analysis, larger summation of largest tumor dimensions was associated with worse BCFI (p = 0.0003), while larger single dimension was associated with worse BCFI (p = 0.02) for MA.12. Presence of MC/MF and other tumor size measurements were not associated (p > 0.05) with BFCI. While physicians could consider the largest diameter of the largest focus of disease or the sum of the largest diameters of all foci in their T-stage determination, it appears that the current method of T-staging offers equivalent determinations of prognosis.
Collapse
Affiliation(s)
- J F Hilton
- NCIC Clinical Trials Group, Queens University, Kingston, ON, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Affiliation(s)
- John F Hilton
- Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA
| | | |
Collapse
|
24
|
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors are pharmacologic agents which primarily inhibit the PARP-1 and PARP-2 enzymes within the cell. Inhibition of PARP results in failure of base-excision repair (BER) to correct single-stranded breaks in DNA. This failure results in double-stranded breaks that are subsequently repaired either by homologous recombination (HR) repair, which is error-free, or by non-homologous end joining (NHEJ), which is an error-prone process. Clinically, PARP inhibitors demonstrate activity in tumors which lack a functional HR system (i.e. BRCA1 and BRCA2 mutations) by forcing NHEJ repair. Known as synthetic lethality, the use of NHEJ in these tumors generates genomic instability and eventual cell death due to rapid development of non-viable genetic errors. In addition due their BER effects, PARP inhibitors are being developed as chemotherapy and radiation sensitizers in a number of tumor types. This review will examine the role of the PARP enzymes in DNA repair, PARP inhibitors in HR-deficient tumors, current results of clinical studies of PARP inhibitors and research efforts to expand the clinical activity of PARP inhibitors beyond HR-deficient tumors.
Collapse
Affiliation(s)
- John F Hilton
- Early Drug Development Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
| | | | | | | |
Collapse
|
25
|
Bouganim N, Vandermeer L, Kuchuk I, Dent S, Hopkins S, Song X, Robbins D, Spencer P, Mazzarello S, Hilton JF, Amir E, Dranitsaris G, Addison C, Mallick R, Clemons MJ. Abstract P3-13-05: Evaluating efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. TRIUMPH: A pragmatic multicentre trial. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-13-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Optimal bisphosphonate (BP) dosing intervals for breast cancer patients (pts) with bone metastases (BM) remain unknown. BP are usually prescribed q3-4 wk regardless of individual pt risk for skeletal related events (SREs). Recent evidence (Amadori J Clin Oncol, 2012 suppl; abstr 9005) shows that q12 wk BP is as effective as q4 wk in pts previously treated with >9 cycles of q4 wk therapy. Hence, further evaluation of modified BP dosing strategies is warranted. The objective of the current study was to show in women with biochemically defined low-risk bone disease that IV BP use every q12 wk for 1 year is sufficient to maintain stability of the bone turnover [measured by serum c-telopeptide (CTx) or bone specific alkaline phosphatase (BSAP)].
Methods: Eligible pts with BM, who had received >3 months of q3-4 wk IV BP and no systemic treatment change within 4 wks of study entry were enrolled. Low risk was defined as serum CTx <600 ng/L. Biochemical failure was defined as CTx levels >600 ng/L at baseline, weeks 6, 12, 24, 36 or 48. Evaluation of palliative benefit of 12-wk IV BP therapy was measured by SREs, analgesic use, and self-reported pain (BPI and FACT-BP).
Results: Between Oct. 2010-Sept. 2011, 85 pts consented to screening, with 13 found ineligible. In the 71 accrued pts baseline characteristics were: mean age 60 (SD 13), median time from breast cancer diagnosis to development of bone metastases 4 months (IQR 82), median duration of prior BP therapy 14 months (IQR 19), and mean number of SREs/yr prior to entering study 0.35 (SD 0.76). Baseline median CTx was 120 ng/L (IQR 240) and BSAP 9.2 IU/L (IQR 3). To date: 26/71 pts (36%) remain on study. Reasons for coming off study include; study completion (18), elevation of CTx >600ng/L (10), or on study SRE (3). An elevation of CTx between baseline and wk 6 was significantly associated with coming off study early (p = 0.008). For pts who had had an SRE before study entry the odds ratios for coming off study early due to an on study SRE or elevated CTx was 1.005 (CI 1.002–1.009; p = 0.007) and for coming off early for an SRE was 0.0245 (CI 0.061–0.094; p = 0.046) respectively. Of the 8/13 pts who were ineligible due to baseline CTx >600ng/L, 6 had an SRE within 1 year of screening.
Conclusion: De-escalating BP therapy to 12 weekly in low risk pts has advantages for both the pt and the health care system. Individual risk of SREs is highly variable, however baseline serum CTx levels <600 ng/L is associated with a low risk of subsequent SREs. While larger trials are required to assess whether increasing CTx with de-escalated therapy will lead to higher rates of SREs or not (Coleman et al. J Clin Oncol 2012 suppl; abstr 511). However, the results of this study and Amadori et al. would suggest that de-escalated BP treatment will likely become a new standard of care after a limited period of q 4wk treatment.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-13-05.
Collapse
Affiliation(s)
- N Bouganim
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - L Vandermeer
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - I Kuchuk
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - S Dent
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - S Hopkins
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - X Song
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - D Robbins
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - P Spencer
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - S Mazzarello
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - JF Hilton
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - E Amir
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - G Dranitsaris
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - C Addison
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - R Mallick
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| | - MJ Clemons
- McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON
| |
Collapse
|
26
|
Daneshmand M, Hanson JEL, Nabavi M, Hilton JF, Vandermeer L, Kanji F, Dent SF, Clemons M, Lorimer IAJ. Detection of PIK3CA Mutations in Breast Cancer Bone Metastases. ISRN Oncol 2012; 2012:492578. [PMID: 22970388 PMCID: PMC3437296 DOI: 10.5402/2012/492578] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/28/2012] [Accepted: 06/25/2012] [Indexed: 12/13/2022]
Abstract
Background. An important goal of personalized cancer therapy is to tailor specific therapies to the mutational profile of individual patients. However, whole genome sequencing studies have shown that the mutational profiles of cancers evolve over time and often differ between primary and metastatic sites. Activating point mutations in the PIK3CA gene are common in primary breast cancer tumors, but their presence in breast cancer bone metastases has not been assessed previously.
Results. Fourteen patients with breast cancer bone metastases were biopsied by three methods: CT-guided bone biopsies; bone marrow trephine biopsies; and bone marrow aspiration. Samples that were positive for cancer cells were obtained from six patients. Three of these patients had detectable PIK3CA mutations in bone marrow cancer cells. Primary tumor samples were available for four of the six patients assessed for PIK3CA status in their bone metastases. For each of these, the PIK3CA mutation status was the same in the primary and metastatic sites. Conclusions. PIK3CA mutations occur frequently in breast cancer bone metastases. The PIK3CA mutation status in bone metastases samples appears to reflect the PIK3CA mutation status in the primary tumour. Breast cancer patients with bone metastases may be candidates for treatment with selective PIK3CA inhibitors.
Collapse
Affiliation(s)
- Manijeh Daneshmand
- Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Naseem M, Murray J, Hilton JF, Han D, Hogeveen S, Heersink RL, Muradali D, Simmons C, Bell D, Haq R, Brezden-Masley C. P5-08-04: Mammographic Microcalcifications and Breast Cancer Tumorigenesis: A Radiologic-Pathologic Analysis. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-08-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Microcalcifications (MCs) are tiny deposits of calcium in breast soft tissue. They serve as key diagnostic radiological features for localization of malignancy. Approximately 30% of early invasive breast cancers have fine, granular MCs detectable on mammography; however, their role in breast cancer tumorigenesis is currently unknown. The purpose of this study was to investigate the relationship between mammographic MCs and breast cancer pathology.
Methods: A retrospective chart review was performed for 882 women treated for breast cancer between 2000–2010 at St. Michael's Hospital. Demographic information (age and menopausal status), tumor pathology (size, histology, grade, nodal status and lymphovascular invasion), hormonal status (ER and PR), HER-2 overexpression and presence of MCs were collected for breast cancer patients. Chi-square tests were performed for categorical variables and t-tests were performed for continuous variables. All tests were two-sided and p-values less than 0.05 were considered statistically significant.
Results: A total of 826 patient charts were included; 56 (6.4%) patients had metastatic carcinoma and were excluded from analysis. Only 37.0% (326/882) of the patients presented with mammographic MCs. Patients were more likely to have MCs if they were HER-2 positive (51%) as opposed to being HER-2 negative (33.4%) (p=0.001). There was a significant association between MCs and being perimenopausal with a mean age of 50 (65.2%) (p=0.012). Patients with invasive ductal carcinomas (39.7%) were more likely to present with MCs than were patients with other tumor histology (p=0.001). There was a positive correlation between MCs and tumor grade (p=0.051), with grade III tumors (41.85%) presenting with the most MCs, followed by grade II (37.95%) and grade I (29.8%). There was no significant association between mean age, mean tumor size, ER and PR status with the presence of MCs.
Conclusion: This is the largest study that suggests the appearance of MCs on mammograms is strongly associated with HER-2 overexpression, invasive ductal carcinoma and perimenopausal status. Since HER-2 is implicated in mediating aggressive tumor growth and metastasis, future studies should investigate the molecular pathways underlying HER-2 overexpression and MC development. This would help better understand the role of MCs in breast cancer tumorigenesis.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-08-04.
Collapse
Affiliation(s)
- M Naseem
- 1St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada
| | - J Murray
- 1St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada
| | - JF Hilton
- 1St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada
| | - D Han
- 1St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada
| | - S Hogeveen
- 1St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada
| | - RL Heersink
- 1St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada
| | - D Muradali
- 1St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada
| | - C Simmons
- 1St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada
| | - D Bell
- 1St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada
| | - R Haq
- 1St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada
| | - C Brezden-Masley
- 1St. Michael's Hospital, Toronto, Canada; University of Toronto, Toronto, Canada
| |
Collapse
|
28
|
Hilton JF, Dong B, Bouganim N, Chapman JAW, Arnaout A, O'Malley F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan T, Pritchard KI, Shepherd L, Clemons M. P2-12-27: Simply Adding Together the Diameters of Tumor Foci in Patients with Multicentric or Multifocal Disease Does Not Add Any Additional Prognostic Information: An Analysis from NCIC CTG MA.12 Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women with Early Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A common clinical conundrum in breast cancer management is whether pathologic T stage in women with multicentric or multifocal disease should be taken as the diameter of the largest focus or as the sum of all foci in the breast. Most staging systems, such as the American Joint Committee on Cancer (AJCC), simply use the largest tumor focus for staging. We examine here the impact of alternate methods of estimating tumour size including measures of total tumor size, volume and surface area.
Materials & Methods: NCIC CTG MA.12 is a randomized placebo-controlled trial of tamoxifen after adjuvant chemotherapy for pre-menopausal women with early breast cancer. Median follow up is 9.7 years. Pathologically reported patient tumor dimensions for up to 3 foci were utilized to examine the effects of tumor size on Breast-Cancer-Free-Interval (BCFI), defined as the time from randomization until recurrence (defined as first local, regional, distant, or contralateral invasive tumor or DCIS). Tumor size was estimated as 1) pathologic T stage as per AJCC criteria; 2) largest dimension of largest tumor focus (cm); 3) sum of largest dimension(s) of tumor foci (cm); 4) sum of surface area(s) of tumor foci (cm2), and 5) sum of volume of tumor foci (cm3). Step-wise forward unstratified Cox regression was used to assess the different effects of tumor size. Results: This study accrued 672 patients, 43% with T1 tumors, 51% with T2 tumors, and 6% with T3/T4 tumors; 25% were node negative and 56% had 1–3 positive lymph nodes. 75% were locally determined to have hormone receptor positive tumors. A higher number of involved lymph nodes was associated with significantly shorter BCFI (p<0.0001). None of pathologic T stage (p=0.14), largest dimension of largest tumor size (p=0.14), sum of largest dimensions of tumor foci (p=0.24), sum of surface area (p=0.38), and sum of volume of foci (p=0.51) were significantly associated with BCFI. Likewise, lymphovascular invasion (p=0.08), grade (p=0.14), nor administration of anthracycline therapy (p=0.08) were associated with BCFI.
Discussion: In the MA.12 population of pre-menopausal women randomized to either tamoxifen or placebo, the sole factor significantly associated with BCFI was nodal status. No measure of tumor size in unifocal or multicentric/multifocal tumors impacted BCFI. The findings of this mature data set suggest that simply adding together the diameters of tumors in patients with multicentric or multifocal disease did not add any additional prognostic information.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-27.
Collapse
Affiliation(s)
- JF Hilton
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - B Dong
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - N Bouganim
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - J-AW Chapman
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - A Arnaout
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - F O'Malley
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - T Nielsen
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - K Gelmon
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - R Yerushalmi
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - M Levine
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - V Bramwell
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - T Whelan
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - KI Pritchard
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - L Shepherd
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - M Clemons
- 1Queens University, Kingston, ON, Canada; The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada; Odette Cancer Centre, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
29
|
Bouganim N, Dong B, Hilton JF, Chapman JAW, Arnaout A, O'Malley F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Bramwell V, Whelan T, Pritchard KI, Shepherd L, Clemons M. P2-12-23: How Should We Assess Tumour Size (T Stage) in Patients with Multicentric/Multifocal Breast Cancer? Results from the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal Women with Node Positive Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
A common clinical conundrum in breast cancer management is whether pathologic T stage in women with multicentric or multifocal disease should be taken as the diameter of the largest focus or as the sum of all foci in the breast. Most staging systems, such as the American Joint Committee on Cancer (AJCC), simply use the largest tumour focus for staging. We examine here the impact of alternate methods of estimating tumour size including measures of total tumour size, volume and surface area.
Methods: NCIC CTG MA.5 is a randomized trial of CEF versus CMF in pre-menopausal women with node positive breast cancer.
Median follow up is 10 years. Pathologically reported patient tumour dimensions for up to 3 foci were utilized to examine the effects of tumour size on Breast-Cancer-Free-Interval (BCFI). BCFI is defined as the time from randomization until recurrence: first local invasive or DCIS, regional, distant, contralateral invasive or DCIS. Tumour size was estimated as 1) pathologic T stage as per AJCC criteria; 2) largest dimension of largest tumour focus (cm); 3) sum of largest dimension(s) of tumour foci (cm); 4) sum of surface area(s) of tumour foci (cm2), and 5) sum of volume of tumour foci (cm3). Step-wise forward unstratified Cox regression was used to assess the different effects of tumour size.
Results: This study accrued 710 patients, 37% with T1 tumours, 52% with T2 tumours and 9% with T3 tumours; 61% had 1 to 3 positive lymph nodes. 59% hormone receptor positive. Higher pathologic T stage (p=0.001) and greater surface area (p=0.02) were associated with shorter BCFI, as was lymphovascular invasion (p=0.03), and # of lymph nodes involved (p<0.0001). Administration of anthracycline therapy led to significantly longer BCFI (0.003). The sum of largest tumour sizes (p=0.33) and sum of tumour volume (p=0.34) were not significantly associated with BCFI. Additionally, when the less complete locally reported tumour grade data were included, higher tumour grade was associated with shorter BCFI (p<0.0001).
Conclusions: Consideration of multicentric and multifocal disease was an important adjunct to standard pathologic tumour size as was estimation of tumour surface area in this chemotherapy trial of node positive premenopausal women. However, simply adding together the diameters of tumours in patients with multicentric or multifocal disease did not add any additional prognostic information in this high risk patient population.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-23.
Collapse
Affiliation(s)
- N Bouganim
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - B Dong
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - JF Hilton
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - J-AW Chapman
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - A Arnaout
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - F O'Malley
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - T Nielsen
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - K Gelmon
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - R Yerushalmi
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - M Levine
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - V Bramwell
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - T Whelan
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - KI Pritchard
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - L Shepherd
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| | - M Clemons
- 1The Ottawa Cancer Center, Ottawa, ON, Canada; Queens University, Kingston, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; Mount Sinai Hospital-University of Toronto, Toronto, ON, Canada; Vancouver Hospital and Health Sciences Center, Vancouver, BC, Canada; BC Cancer Agency-University of British Columbia, Vancouver, BC, Canada; Juravinski Cancer Center-McMaster University, Hamilton, ON, Canada; Tom Baker Cancer Center-University of Calgary, Calgary, AB, Canada; Odette Cancer Center-University of Toronto, Toronto, ON, Canada
| |
Collapse
|
30
|
Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O'Callaghan CJ, Tu D, Parulekar W, Moore MJ. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer 2011; 48:1434-42. [PMID: 22119354 DOI: 10.1016/j.ejca.2011.10.035] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2011] [Revised: 09/07/2011] [Accepted: 10/24/2011] [Indexed: 11/13/2022]
Abstract
BACKGROUND The effect of comorbidity, age and performance status (PS) on treatment of advanced pancreatic cancer is poorly understood. We examined these factors as predictors of outcome in advanced pancreatic cancer patients treated with gemcitabine +/- erlotinib. PATIENTS AND METHODS Comorbidity was evaluated by two physicians using the Charlson Comorbidity Index (CCI) and correlated with clinical outcome data from the NCIC Clinical Trials Group (NCIC CTG) PA.3 clinical trial. RESULTS Five hundred and sixty-nine patients were included; 47% were aged ≥ 65 years old, 36% had comorbidity (CCI>0). In multivariate analysis, neither age (p=0.22) nor comorbidity (p=0.21) was associated with overall survival. The baseline presence of better PS and lower pain intensity scores was associated with better overall survival (p < 0.0001 and p=0.01, respectively). An improvement in survival with the addition of erlotinib therapy was seen in patients age < 65 (adjusted hazard ratio (HR) 0.73, p=0.01) or in the presence of comorbidity (adjusted HR 0.72, p=0.03). However, neither age nor CCI score was predictive of erlotinib benefit after test for interaction. Patients treated with gemcitabine plus erlotinib who were ≥ 65 years of age or those with comorbidity had a higher rate of infections ≥ grade 3. CONCLUSION Low baseline pain intensity and better PS were associated with improved overall survival, while age and comorbidity were not independent prognostic factors for patients treated with gemcitabine-based therapy.
Collapse
Affiliation(s)
- M M Vickers
- Department of Oncology, Tom Baker Cancer Centre, Alberta, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Staninec M, Nalla RK, Hilton JF, Ritchie RO, Watanabe LG, Nonomura G, Marshall GW, Marshall SJ. Dentin erosion simulation by cantilever beam fatigue and pH change. J Dent Res 2005; 84:371-5. [PMID: 15790746 DOI: 10.1177/154405910508400415] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Exposed root surfaces frequently exhibit non-carious notches representing material loss by abrasion, erosion, and/or abfraction. Although a contribution from mechanical stress is often mentioned, no definitive proof exists of a cause-effect relationship. To address this, we examined dimensional changes in dentin subjected to cyclic fatigue in two different pH environments. Human dentin cantilever-beams were fatigued under load control in pH = 6 (n = 13) or pH = 7 (n = 13) buffer, with a load ratio (R = minimum load/maximum load) of 0.1 and frequency of 2 Hz, and stresses between 5.5 and 55 MPa. Material loss was measured at high- and low-stress locations before and after cycling. Of the 23 beams, 7 withstood 1,000,000 cycles; others cracked earlier. Mean material loss in high-stress areas was greater than in low-stress areas, and losses were greater at pH = 6 than at pH = 7, suggesting that mechanical stress and lower pH both accelerate erosion of dentin surfaces.
Collapse
Affiliation(s)
- M Staninec
- UCSF School of Dentistry, Box 0758, San Francisco, CA 94143, USA.
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Weintraub JA, Hilton JF, White JM, Hoover CI, Wycoff KL, Yu L, Larrick JW, Featherstone JDB. Clinical trial of a plant-derived antibody on recolonization of mutans streptococci. Caries Res 2005; 39:241-50. [PMID: 15914988 DOI: 10.1159/000084805] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2004] [Accepted: 10/12/2004] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE This double-blinded, placebo-controlled clinical trial tested the safety and efficacy of a topical secretory IgA antibody manufactured in tobacco plants (plantibody) in preventing recolonization of mutans streptococci (MS) in human plaque as measured by whole stimulated saliva samples. METHODS Following a 9-day antimicrobial treatment with chlorhexidine (CHX), 56 eligible adults (enrollment salivary MS > or = 10(4) CFU/ml; no current caries) were randomized equally to a group receiving 0, 2, 4, or 6 topical applications of plantibody followed by 6, 4, 2, or 0 applications of placebo, respectively, over a 3-week period. RESULTS Among the 54 subjects who completed the trial, the CHX regimen eliminated salivary MS in 69%. After 6 months, there were no significant differences in MS levels by number of applications, relative to placebo (p > 0.43). No adverse effects were observed. CONCLUSION Plantibody is safe but not effective at the frequency, concentration, and number of applications used in this study.
Collapse
Affiliation(s)
- J A Weintraub
- Department of Preventive and Restorative Dental Sciences, School of Dentistry, University of California-San Francisco, 3333 California Street, San Francisco, CA 94143-1361, USA.
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Hilton JF, Christensen KE, Watkins D, Raby BA, Renaud Y, de la Luna S, Estivill X, MacKenzie RE, Hudson TJ, Rosenblatt DS. The molecular basis of glutamate formiminotransferase deficiency. Hum Mutat 2003. [DOI: 10.1002/humu.10281] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
34
|
Hilton JF, Christensen KE, Watkins D, Raby BA, Renaud Y, de la Luna S, Estivill X, MacKenzie RE, Hudson TJ, Rosenblatt DS. The molecular basis of glutamate formiminotransferase deficiency. Hum Mutat 2003; 22:67-73. [PMID: 12815595 DOI: 10.1002/humu.10236] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Glutamate formiminotransferase deficiency, an autosomal recessive disorder and the second most common inborn error of folate metabolism, is presumed to be due to defects in the bifunctional enzyme glutamate formiminotransferase-cyclodeaminase (FTCD). Features of a severe phenotype, first identified in patients of Japanese descent, include elevated levels of formiminoglutamate (FIGLU) in the urine in response to histidine administration, megaloblastic anemia, and mental retardation. Features of a mild phenotype include high urinary excretion of FIGLU in the absence of histidine administration, mild developmental delay, and no hematological abnormalities. We found mutations in the human FTCD gene in three patients with putative glutamate formiminotransferase deficiency. Two siblings were heterozygous for missense mutations, c.457C>T (R135C) and c.940G>C (R299P). Mutagenesis of porcine FTCD and expression in E. coli showed that the R135C mutation reduced formiminotransferase activity to 61% of wild-type, whereas the R299P mutation reduced this activity to 57% of wild-type. The third patient was hemizygous for c.1033insG, with quantitative PCR indicating that the other allele contained a deletion. These mutations are the first identified in glutamate formiminotransferase deficiency and demonstrate that mutations in FTCD represent the molecular basis for the mild phenotype of this disease.
Collapse
Affiliation(s)
- John F Hilton
- Department of Biology, McGill University, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
Enamel fluorosis is characterised by increased porosity and a delay in the removal of enamel matrix proteins as the enamel matures. Amelogenin is the primary matrix protein in secretory-stage dental enamel. As enamel matures, amelogenins are hydrolysed by a number of enamel proteinases, including matrix metalloproteinase-20 (MMP-20 or enamelysin) and serine proteinase. Here, the effect of ingested fluoride on the relative activity of proteinases in the enamel matrix and the specific effect of fluoride on MMP-20 activity were examined. Proteinase activity relative to total enamel matrix protein was measured by fluorescence assay of enamel matrix dissected from rats given 0, 50, or 100 parts per 10(6) fluoride in their drinking water. To determine the specific effect of fluoride on the activity of MMP-20, the hydrolysis of a full-length recombinant human amelogenin by recombinant MMP-20 (rMMP-20) in the presence of 0, 2, 5, 10 or 100 microM fluoride was compared by sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE). In addition, a fluorescent peptide assay was developed to quantify enzyme activity against the tyrosine-rich amelogenin peptide cleavage site. In the late maturation stage, total proteinase activity per unit protein was lower in the fluoride-exposed rats than in the control rats. This in vivo finding indicates that fluoride ingestion can alter the relative amount of active proteinase in mature enamel. Hydrolysis of amelogenin at neutral pH by rMMP-20 was reduced in the presence of 100 microM F. In the peptide assay, rMMP-20 activity was significantly reduced by concentrations of fluoride as low as 2 microM at pH 6, with no significant effect at pH 7.2. These in vitro assays show that micromolar concentrations of fluoride can alter metalloproteinase activity, particularly when the pH is reduced to 6.0. These studies suggest that the effects of fluoride on enamel matrix proteinase secretion or activity could be involved in the aetiology of fluorosis in enamel and other mineralising tissues.
Collapse
Affiliation(s)
- P K DenBesten
- Growth and Development Department, School of Dentistry, University of California at San Francisco, 521 Parnassus Avenue, Room C735, San Francisco, CA 94143-0640, USA.
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
OBJECTIVE Dentin structure varies with orientation and location. Ultimate shear strength (USS) has also been found in previous studies to vary with location. The present study further explores this relationship between USS and various locations in coronal dentin as well as distance from the pulp. METHODS Stick specimens were prepared from coronal dentin located in the center or under cusps of human molar teeth. These were tested in the shear mode at various distances from the pulp. RESULTS Median values ranged from 52.7 (range 29.0-73.1) MPa near the pulp to 76.7 (range 53.9-104.0) MPa near the dentino-enamel junction. No differences were found among the buccal, central or lingual locations, however, the USS near the pulp was found to be significantly lower. SIGNIFICANCE The properties of coronal dentin vary with distance from the pulp, which may affect adhesion and other aspects of restorative dentistry.
Collapse
Affiliation(s)
- N Konishi
- Department of Operative Dentistry, Okayama University Graduate School of Medicine and Dentistry, Field of Study of Biofunctional Recovery and Reconstruction, Okayama, Japan
| | | | | | | | | | | |
Collapse
|
37
|
Watkins D, Ru M, Hwang HY, Kim CD, Murray A, Philip NS, Kim W, Legakis H, Wai T, Hilton JF, Ge B, Doré C, Hosack A, Wilson A, Gravel RA, Shane B, Hudson TJ, Rosenblatt DS. Hyperhomocysteinemia due to methionine synthase deficiency, cblG: structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173L. Am J Hum Genet 2002; 71:143-53. [PMID: 12068375 PMCID: PMC384971 DOI: 10.1086/341354] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2002] [Accepted: 04/22/2002] [Indexed: 11/03/2022] Open
Abstract
Mutations in the MTR gene, which encodes methionine synthase on human chromosome 1p43, result in the methylcobalamin deficiency G (cblG) disorder, which is characterized by homocystinuria, hyperhomocysteinemia, and hypomethioninemia. To investigate the molecular basis of the disorder, we have characterized the structure of the MTR gene, thereby identifying exon-intron boundaries. This enabled amplification of each of the 33 exons of the gene, from genomic DNA from a panel of 21 patients with cblG. Thirteen novel mutations were identified. These included five deletions (c.12-13delGC, c.381delA, c.2101delT, c.2669-2670delTG, and c.2796-2800delAAGTC) and two nonsense mutations (R585X and E1204X) that would result in synthesis of truncated proteins that lack portions critical for enzyme function. One mutation was identified that resulted in conversion of A to C of the invariant A of the 3' splice site of intron 9. Five missense mutations (A410P, S437Y, S450H, H595P, and I804T) were identified. The latter mutations, as well as the splice-site mutation, were not detected in a panel of 50 anonymous DNA samples, suggesting that these sequence changes are not polymorphisms present in the general population. In addition, a previously described missense mutation, P1173L, was detected in 16 patients in an expanded panel of 24 patients with cblG. Analysis of haplotypes constructed using sequence polymorphisms identified within the MTR gene demonstrated that this mutation, a C-->T transition in a CpG island, has occurred on at least two separate genetic backgrounds.
Collapse
Affiliation(s)
- David Watkins
- Division of Medical Genetics, Department of Medicine, McGill University Health Centre, Montreal, Quebec, H3A 1A1, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Hilton JF, Alves M, Anastos K, Canchola AJ, Cohen M, Delapenha R, Greenspan D, Levine A, MacPhail LA, Micci SJ, Mulligan R, Navazesh M, Phelan J, Tsaknis P. Accuracy of diagnoses of HIV-related oral lesions by medical clinicians. Findings from the Women's Interagency HIV Study. Community Dent Oral Epidemiol 2001; 29:362-72. [PMID: 11553109 DOI: 10.1034/j.1600-0528.2001.290506.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To determine if medical clinicians are as accurate as dental clinicians in recognizing diagnostic characteristics of HIV-related oral lesions. METHODS In 355 HIV-infected participants at five Women's Interagency HIV Study sites, we paired oral examinations conducted within 7 days of each other by dental and medical clinicians. We used the former as a gold standard against which to evaluate the accuracy of the latter. We assessed the accuracy of the medical clinicians' findings based both on their observations of abnormalities and on their descriptions of these abnormalities. RESULTS Dental clinicians diagnosed some oral abnormality in 38% of participants. When "abnormality" was used as the medical clinicians' outcome, sensitivities were 75% for pseudomembranous candidiasis and 58% for erythematous candidiasis, but only 40% for hairy leukoplakia. When a precise description of the abnormality was used as their outcome, sensitivities were 19%, 12% and 20%, respectively. CONCLUSIONS Medical clinicians recognize that HIV-related oral abnormalities are present in 40-75% of cases, but less often describe them accurately. Low sensitivity implies that the true associations of specific oral lesions with other HIV phenomena, such as time until AIDS, must be stronger than the literature suggests.
Collapse
Affiliation(s)
- J F Hilton
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94143-0560, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Kaplan CP, Hilton JF, Park-Tanjasiri S, Pérez-Stable EJ. The effect of data collection mode on smoking attitudes and behavior in young African American and Latina women. Face-to-face interview versus self-administered questionnaires. Eval Rev 2001; 25:454-473. [PMID: 11480308 DOI: 10.1177/0193841x0102500403] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Evaluating smoking prevention and cessation programs requires valid data collection. This study examined two survey modes--face-to-face (FTF) interview and self-administered questionnaire (SAQ)--comparing response rates, sample characteristics, data quality, and response effects. From two family planning clinics, 601 female Latina and African American clients ages 12 to 21 were recruited and randomized to either group. Results reveal that neither mode is superior to the other. The SAQ may therefore be preferable for this population, despite its higher rate of incompletes, because it yields results similar to the FTF yet is more cost effective and less disruptive to clinic routines.
Collapse
Affiliation(s)
- C P Kaplan
- University of California, San Francisco, USA
| | | | | | | |
Collapse
|
40
|
Abstract
OBJECTIVE To describe the prevalence, patterns, and correlates of spit (smokeless) tobacco (ST) use in a sample of high school baseball athletes in California. DESIGN This cross sectional study was a survey of 1226 baseball athletes attending 39 California high schools that were randomly selected from a list of all publicly supported high schools with baseball teams. At a baseball team meeting, athletes who agreed to participate and had parental consent completed the study questionnaire. To enhance the accuracy of self reported ST use status, a saliva sample was collected from each subject. The questionnaires and saliva samples were coded and salivary cotinine assay was performed on a random subsample of 5% of non-users who also were non-smokers. Biochemical assay indicated that 2% tested positive for cotinine inconsistent with self reported ST non-use. RESULTS Overall, 46% had ever used ST and 15% were current users. Odds ratios and 95% confidence intervals (CI) suggested that, among high school baseball athletes, age, living in a rural area, being white, smoking cigarettes, drinking alcohol, not knowing about the adverse effects of ST, perceiving little personal risk associated with ST use, and believing that friends, role models, teammates, and same age baseball athletes in general used ST, increased the likelihood of being an ST user. CONCLUSION The findings indicate that considerable experimentation with ST products occurs among high school baseball athletes in California, and many are current users. ST interventions targeting this population are needed to stop the transition from experimental ST use to tobacco dependence. Correlates of ST use for consideration in future intervention studies are identified.
Collapse
Affiliation(s)
- M M Walsh
- Department of Dental Public Health and Hygiene, School of Dentistry, University of California, San Francisco 94143-1361, USA.
| | | | | | | | | |
Collapse
|
41
|
Abstract
Although oral candidiasis lesions are widely recognized as markers for AIDS, the relative prognostic significance of functions of these episodes has not been examined. We compare the associations with time to AIDS of one fixed and six time-dependent metrics of oral candidiasis lesions, including proximity of a lesion to seroconversion, any candidiasis history, and recency of a lesion. We show in Cox regression models that two metrics are clinically and statistically far more significant than the others, alone or in combination: any history of candidiasis since HIV seroconversion, and recency of a candidiasis episode. The latter metric indicates that the risk of an AIDS diagnosis is high during a candidiasis episode. The results hold for two cohorts of male seroconverters, 627 haemophiliacs and 196 men who have sex with men. Identification of highly prognostic functions of a patient's oral candidiasis history allows clinicians and researchers to focus on these aspects of the history and to omit extraneous information from data collection. Our method extends well beyond candidiasis and AIDS, and may shed light on associations of covariates with outcomes in a variety of settings.
Collapse
Affiliation(s)
- J F Hilton
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California 94143-0560, USA.
| |
Collapse
|
42
|
Abstract
OBJECTIVE To describe the incidence and prevalence of oral manifestations of HIV infection in a population of perinatally infected children. DESIGN Retrospective and prospective study of a cohort of perinatally HIV-infected children. SETTING Community hospital and community-based paediatric clinic. SAMPLE AND METHODS Forty perinatally HIV-infected children with a median age of 12 months were eligible and selected for the study, which included a medical chart review from birth and prospective follow-up. Each child was examined quarterly for oral manifestations, tooth eruption, and for 27 children, caries and periodontal status. RESULTS The incidence of pseudomembranous candidiasis was 43% (95% CI, 27-58%) within 6 months of birth. Oral candidiasis (defined as pseudomembranous or erythematous) was positively associated with low CD4 counts and the occurrence of plaque. Children with low CD4 counts were also found to have fewer teeth than children with high CD4 counts, after adjusting for age. CONCLUSIONS Oral manifestations are common in paediatric HIV infection and are possible predictors of HIV disease progression. Primary care of HIV-infected children should include periodic oral examinations to monitor their HIV disease progression and to alleviate symptoms associated with oral opportunistic infections.
Collapse
Affiliation(s)
- F J Ramos-Gomez
- Department of Growth and Development, University of California San Francisco, San Francisco, California 94143-0438, USA.
| | | | | | | | | | | |
Collapse
|
43
|
Walsh MM, Hilton JF, Masouredis CM, Gee L, Chesney MA, Ernster VL. Smokeless tobacco cessation intervention for college athletes: results after 1 year. Am J Public Health 1999; 89:228-34. [PMID: 9949754 PMCID: PMC1508522 DOI: 10.2105/ajph.89.2.228] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVES The purpose of this study was to determine the efficacy of a college-based smokeless tobacco cessation intervention targeting college athletes. METHODS Sixteen colleges were matched for prevalence of smokeless tobacco use in their combined baseball and football teams and randomly assigned within college pairs to the intervention or the control group. One-year prevalence of cessation among smokeless tobacco users was determined by self-report of abstinence for the previous 30 days. Differences between groups were analyzed in a weighted version of the Fisher 1-sided permutation test for paired samples after adjustment for significant predictors of quitting other than the intervention (i.e., smokeless tobacco uses per week and most frequently used brand). RESULTS Cessation prevalences were 35% in the intervention colleges and 16% in the control colleges when subjects with unknown quit status were defined as nonquitters. After adjustment for other significant predictors of quitting, the difference of 19% increased to 21%. The intervention effect increased with level of smokeless tobacco use. CONCLUSIONS This intervention was effective in promoting smokeless tobacco cessation, especially among those who were more frequent users.
Collapse
Affiliation(s)
- M M Walsh
- Department of Dental Public Health and Hygiene, University of California, San Francisco 94143-1361, USA
| | | | | | | | | | | |
Collapse
|
44
|
Greenspan JS, De Souza YG, Regezi JA, Daniels TE, Greenspan D, MacPhail LA, Hilton JF. Comparison of cytopathic changes in oral hairy leukoplakia with in situ hybridization for EBV DNA. Oral Dis 1998; 4:95-9. [PMID: 9680897 DOI: 10.1111/j.1601-0825.1998.tb00264.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE It has been observed that the cytopathic changes in hairy leukoplakia (HL) correlate with ultrastructural evidence of intra-keratinocyte herpes-type viral particles. In situ hybridization is considered to be the definitive confirmation of Epstein-Barr virus (EBV)-induced HL. This study evaluated the consistency of histopathological findings, which many believe to be diagnostic, with in situ hybridization for EBV-DNA in 60 patients with lesions clinically suggestive of HL. MATERIALS AND METHODS Hematoxylin and eosin (H&E)-stained sections were reviewed independently by three oral pathologists who did not know the hybridization results. The presence in keratinocytes of nuclear inclusions and/or homogenization, believed to be specific for EBV in these lesions, was used as an indicator for infection. Cytoplasmic changes were evaluated separately. RESULTS With in situ hybridization, 48 cases were positive and 12 were negative. When the two methods were compared, pathologist concurrence ranged from 83% to 92%. False negatives ranged from 6% to 19%, and false positives ranged from 8% to 25%. Cytoplasmic ballooning, homogenization, and perinuclear clearing were evident in all cases of hybridization-confirmed HL; however, these changes were also noted in 75% (9/12) of the cases with negative hybridization results. Most confirmed HL cases exhibited both nuclear homogenization and inclusions, although the former was more consistently seen. CONCLUSION Cytoplasmic changes did not agree well with EBV-DNA hybridization results, whereas nuclear changes demonstrated good, but not complete, agreement. In appropriate clinical settings, the finding of nuclear inclusions and/or homogenization may be of diagnostic value. However, because the potential for false positives and negatives is high, H&E cytopathology should not be used as a substitute for in situ hybridization in the definitive diagnosis of oral hairy leukoplakia.
Collapse
Affiliation(s)
- J S Greenspan
- Department of Stomatology and Oral AIDS Center, University of California San Francisco, USA. stom%
| | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
OBJECTIVES Mucocutaneous diseases are common in patients infected with human immunodeficiency virus (HIV). To identify cutaneous diseases for which HIV-infected people are at high risk, we sought those that are strongly associated with specific HIV-related oral lesions and with progression of HIV disease. DESIGN A cross-sectional study of HIV-positive outpatients referred to a university stomatology clinic for diagnosis and treatment of oral diseases. Each subject underwent both complete oral and cutaneous examinations. RESULTS Among 55 men, with a median age of 41 years and a median CD4 cell count of 125/microliter (range 0-950/microliter), 93% had active oral diseases or conditions, including candidiasis, hairy leukoplakia, ulcers, Kaposi's sarcoma (KS), and xerostomia, and 95% had skin conditions, including onychomycosis, dermatophytosis, seborrheic dermatitis, KS, folliculitis, xerosis, and molluscum contagiosum. Seborrheic dermatitis, xerosis, skin KS, and molluscum contagiosum were associated with oral HIV-sentinel lesions (oral candidiasis, hairy leukoplakia, and KS), with low CD4 cell counts, and with AIDS. CONCLUSION Our results suggest that xerosis and seborrheic dermatitis may be early harbingers of HIV disease progression. Their roles as predictors warrant further study, based on their associations with low CD4 cell counts and AIDS and strong co-prevalence with one of the most common HIV-related oral lesions, oral candidiasis.
Collapse
Affiliation(s)
- G W Mirowski
- Department of Dermatology, Indiana University, Indianapolis 46202, USA
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Masouredis CM, Hilton JF, Grady D, Gee L, Chesney M, Hengl L, Ernster V, Walsh MM. A spit tobacco cessation intervention for college athletes: three-month results. Adv Dent Res 1997; 11:354-9. [PMID: 9524436 DOI: 10.1177/08959374970110030801] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Sixteen colleges were matched on the baseline prevalence of spit tobacco (ST) use, and college pairs were randomized, one to the intervention and the other to the control group. Baseball and football athletes at each intervention college received: an oral examination by a dental professional who pointed out ST-related problems in the athlete's mouth and advised him to quit ST use; counseling by a dental hygienist on strategies to cope with cravings and triggers for use; and two follow-up telephone calls. At the three-month follow-up, quit rates were 24% and 16% for the intervention (n = 171) and control (n = 189) groups, respectively (p < 0.05). As the reported amount of ST used weekly increased, the percent of individuals who quit at 3 mos decreased (p < 0.05). Dental professionals appear to be effective in promoting spit tobacco cessation at 3 mos post-intervention in male college athletes, especially among those using lesser amounts of ST.
Collapse
Affiliation(s)
- C M Masouredis
- Department of Dental Public Health and Hygiene, University of California, San Francisco 94143-0754, USA
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
To determine whether the presence of specific oral lesions is associated with cigarette smoking among HIV-infected patients, we analyzed cross-sectional data (CD4 cell count, smoking history, and oral examination findings) from 1,058 HIV-infected male patients who received clinical care at the University of California, San Francisco. Oral AIDS Center Clinic. To control for potential confounding by the level of immune suppression, final analyses were limited to participants (n = 693) on whom CD4 cell count data (within 180 days of study visit) were available. Six percent of subjects had normal examination findings, 16% had nonnormal findings (but none of the six lesions of interest), 47% had lesions of a single type, and 31% had a combination of two or more types of lesions. After adjusting for CD4 cell count, current smokers were significantly more likely to have candidiasis (odds ratio [OR] = 1.84; 95% confidence interval [CI] 1.34-2.54) and warts (OR = 2.09; 95% CI 1.15-3.81) and less likely to have aphthous ulcers (OR = 0.24; 95% CI 0.14-0.42) than were current nonsmokers. These results suggest a strong association between cigarette smoking and the presence of specific HIV-related oral lesions.
Collapse
Affiliation(s)
- H Palacio
- Department of Medicine, University of California, San Francisco 94143-0422, USA
| | | | | | | |
Collapse
|
48
|
Gniewek RA, Stites DP, McHugh TM, Hilton JF, Nakagawa M. Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay. Clin Diagn Lab Immunol 1997; 4:185-8. [PMID: 9067653 PMCID: PMC170499 DOI: 10.1128/cdli.4.2.185-188.1997] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Performances of anti-nuclear antibody testing by immunofluorescence assay (ANA-IFA) and enzyme immunoassay (ANA-EIA) were compared in relation to patient diagnosis. A total of 467 patient serum samples were tested by ANA-IFA (Kallestad; Sanofi) and ANA-EIA (RADIAS; Bio-Rad), and their age, sex, diagnosis, disease status, and medications were obtained through chart review. Reference ranges were established by testing 98 healthy blood donor samples. Eighty-six samples came from patients with diffuse connective tissue diseases, including systemic lupus erythematosus, discoid lupus erythematosus, or drug-induced lupus (n = 71); systemic sclerosis, CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal motility abnormalities, sclerodactyly, and telangiectasia), or Raynaud's syndrome (n = 8); Sjögren's syndrome (n = 5); mixed connective tissue disease (n = 5); and polymyositis or dermatomyositis (n = 3). The sensitivity, specificity, positive predictive value, and negative predictive value for ANA-IFA were 87.2, 48.0, 29.1, and 93.9%, respectively, for the reference range of < 1:160. For ANA-EIA, they were 90.7, 60.2, 35.8, and 96.4%, respectively, for the reference range of < 0.9. ANA-EIA offers equivalent sensitivity and higher specificity compared to ANA-IFA.
Collapse
Affiliation(s)
- R A Gniewek
- Bio-Rad Laboratories, Hercules, California 94547, USA
| | | | | | | | | |
Collapse
|
49
|
Hilton JF, Donegan E, Katz MH, Canchola AJ, Fusaro RE, Greenspan D, Greenspan JS. Development of oral lesions in human immunodeficiency virus-infected transfusion recipients and hemophiliacs. Am J Epidemiol 1997; 145:164-74. [PMID: 9006313 DOI: 10.1093/oxfordjournals.aje.a009087] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
The authors used multivariate repeated-measures transition models to identify risk factors for two oral lesions related to human immunodeficiency virus (HIV)-candidiasis and hairy leukoplakia-in 152 HIV-infected blood transfusion recipients and hemophiliacs. Subjects were examined for occurrences of these lesions every 6 months from July 1985 through March 1993, yielding 1,076 study visits. It was found that, after adjustment for the CD4:CD8 T-lymphocyte ratio, patients with a history of candidiasis in the previous 18 months were at high risk of lesion recurrence. This risk increased with the number of prior episodes and with the recency of the episode(s). A history of hairy leukoplakia was less predictive of persistence of that lesion after adjustment for significant risk factors (including candidiasis and use of antifungal agents at the current examination, a low CD4:CD8 cell ratio, and age less than 40 years). The authors also found a high coprevalence of candidiasis and hairy leukoplakia in these subjects. These results suggest that HIV-infected patients with oral candidiasis should be carefully monitored for subsequent episodes over the next 12-18 months, and patients with either oral candidiasis or hairy leukoplakia and a low CD4:CD8 cell ratio should be carefully examined for the other type of lesion as well.
Collapse
Affiliation(s)
- J F Hilton
- Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco 94143-0560, USA
| | | | | | | | | | | | | |
Collapse
|
50
|
Shiboski CH, Hilton JF, Neuhaus JM, Canchola A, Greenspan D. Human immunodeficiency virus-related oral manifestations and gender. A longitudinal analysis. The University of California, San Francisco Oral AIDS Center Epidemiology Collaborative Group. Arch Intern Med 1996; 156:2249-54. [PMID: 8885825 DOI: 10.1001/archinte.156.19.2249] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Because human immunodeficiency virus (HIV) infection affects an increasing number of women in the United States, we investigated the role played by gender in the occurrence of HIV-related oral conditions. METHODS As part of a 4-year prospective study of 3 epidemiological cohorts, oral and physical examinations (including blood tests) were performed on HIV-infected men (n = 200) and women (n = 218) at 6-month intervals. Our outcome variables included oral conditions commonly associated with HIV infection: hairy leukoplakia, candidiasis, ulcers, warts, non-Hodgkin lymphoma, Kaposi sarcoma, and parotid enlargement. RESULTS Only hairy leukoplakia, candidiasis, and ulcers were observed. The occurrence of hairy leukoplakia and candidiasis was higher in men (22% and 24%, respectively) than in women (9% and 13%, respectively) during the study period. A regression model for longitudinal data (generalized estimating equation) disclosed that the odds of having hairy leukoplakia were 2.5 times higher for men than for women, after controlling for CD4+ cell count, race, and injecting drug use (95% confidence interval, 1.34-4.76; P = .003). Length of follow-up did not confound this association. A weaker association was found between the occurrence of oral candidiasis and gender (adjusted odds ratio, 1.85; 95% confidence interval, 1.0-3.43; P = .05). CONCLUSIONS In this sample of HIV-infected adults, we found that men were significantly more likely to have hairy leukoplakia than were women. The hairy leukoplakia-gender association merits further investigation, because it may be related to a gender difference in the mode of expression of Epstein-Barr virus.
Collapse
Affiliation(s)
- C H Shiboski
- Department of Stomatology, University of California, San Francisco, USA
| | | | | | | | | |
Collapse
|